

PLEASE READ AND PROOF EVERYTHING CAREFULLY BEFORE EMAILING YOUR FINAL APPROVAL

Your email with the word **APPROVED** is your final approval and your order for all work to proceed.
Verbal approval will not be accepted.

Please check all spelling, names, addresses,
numbers (phone, fax, mobile, zip codes, dates, times, etc.), general layout, etc.

CHECK EVERY LETTER AND PUNCTUATION MARK

Changes, corrections, and revisions require a revised proof.

Your final approval by email is your formal acknowledgment that
you have the authority to approve this proof and:

- ✓ You have reviewed this proof in its entirety.
- ✓ This proof is acceptable and correct to your satisfaction.
- ✓ You assume all responsibility for the accuracy of this proof.
- ✓ This proof is approved and all work should proceed without delay.

**WE DO NOT ASSUME RESPONSIBILITY FOR ERRORS
OR THEIR RESULTING COMPLICATIONS.**

Please Note: You will be billed for content, layout, and design changes should you choose not to proceed with this order.

2025 ANNUAL REPORT

DEPARTMENT OF MEDICAL ONCOLOGY



Thomas Jefferson University Hospital



Asplundh Cancer Pavilion at Jefferson Health



Jefferson Cherry Hill Hospital



Lehigh Valley Hospital—Muhlenberg



Jefferson Honickman Center



Jefferson Einstein Montgomery Hospital



Jefferson Einstein Philadelphia Hospital



Lehigh Valley Hospital—Hazleton



Jefferson Torresdale Hospital



Lehigh Valley Hospital—Carbon




Jefferson Washington Township Hospital



Lehigh Valley Hospital—Pocono



Lehigh Valley Hospital—Hecktown Oaks



Lehigh Valley Hospital—Schuylkill



Lehigh Valley Hospital—Cedar Crest



Thomas Jefferson
University

HOME OF SIDNEY KIMMEL MEDICAL COLLEGE

TABLE OF CONTENTS

Letter from the Chair	3
In Memorium.	5
Department Overview	7
Clinical Achievements	15
Research Achievements	17
Educational Achievements.	21
Education Programs	25
Quality Achievements	29
Division of Solid Tumor	33
Hospitalists	37
Division of Hematologic Malignancies.	39
Division of Transplant and Cell Therapies	43
Division of Population Science	45
Division of Supportive Oncology	51
Jefferson—Abington Hospital and Asplundh Cancer Pavilion	57
Jefferson—Einstein Philadelphia.	61
Jefferson—Einstein Montgomery (JEM)	65
Jefferson—Northeast (JNE)	67
Jefferson—New Jersey (JNJ)	71
Jefferson—Lehigh Valley Topper Cancer Institute.	73
Publications	81

LETTER FROM THE CHAIR

Dear Colleagues, Patients, and Friends of Jefferson Health,

2025 was a year of meaningful transformation for the Department of Medical Oncology at Thomas Jefferson University and the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Jefferson Health. Across every dimension of our mission—clinical excellence, research innovation, education, and equity—our department demonstrated what is possible when extraordinary people are united by a common purpose.

Expanding Access Across Our Region

We significantly expanded our geographic reach this year, now serving patients across six major regional enterprise sites—from Jefferson Einstein Philadelphia and Montgomery County, to Jefferson Northeast, Jefferson-Abington Asplundh Cancer Center, Jefferson New Jersey, and 15 hospital campuses of Lehigh Valley Health Network, home to the Lehigh Valley Topper Cancer Institute and the John and Dorothy Morgan Cancer Center. The launch of our Same Day/Next Day appointment model reduced time-to-care for new patients and reflects our unwavering commitment to accessibility. Integration of nutritional counseling and depression screening into routine oncology workflows further affirms that we treat the whole person.

Research and Innovation at Scale

Our research enterprise experienced historic growth in 2025. Clinical trial accruals reached 1579 patients—a 1.81% increase over the prior year—providing early access to next-generation immunotherapies, targeted agents, cellular therapies, and population science initiatives. Across our four divisions—Solid Tumor, Hematologic Malignancy, Transplant and Cellular Therapy, and Population Science—our teams continued to push the boundaries of what is possible for our patients and the field.

Education, Advocacy, and the Path Forward

We remain deeply invested in training the next generation of oncologists. Our fellowship program strengthened its commitment to diverse recruitment, ensuring our physician workforce reflects the communities we are privileged to serve. Nationally, our faculty have championed policy reforms to protect the Physician Fee Schedule and preserve the long-term viability of oncology practice. As we look toward 2026 and beyond, our focus will center on building the AI-Integrated Clinic—harnessing predictive analytics to anticipate patient needs, personalize care pathways, and prevent complications before they arise.

None of this is possible without the dedication, resilience, and compassion of our faculty and staff. You are the foundation of every outcome we celebrate and every life we extend. It is a privilege to serve alongside you.

With gratitude and optimism,



Wm. Kevin Kelly, DO, FASCO
Chair, Dept. of Medical Oncology
Professor, Medical Oncology and Urology
Chief of Cancer Services, Sidney Kimmel Comprehensive Cancer Center at Jefferson Health



Our Mission Statement

Reimagining cancer care delivery, discovery, and education.

Our Goals

- To develop a locally and nationally recognized unified Department of Medical Oncology that delivers outstanding, state of the art, and compassionate oncology care seamless in the community and the academic setting.
- To be a national leader in oncology research bringing novel discoveries and therapies to the patient we serve and beyond while increasing extramural funding.
- To nurture, and grow our current medical oncology faculty to ensure they continue to be productive, creative, and compassionate.
- To educate, train, and mentor the next generation of diverse cancer clinicians, researchers, and leaders to continue the growth of the Jefferson Enterprise.
- To expand internal and external collaborations through innovation, novel partnerships, and entrepreneurship to improve cancer care delivery, accelerate discovery, and enhance educational opportunities.

In Memorium

MOUADH BARBIROU, MSc, PhD

We were sad to hear of the passing of **Mouadh Barbirou, MSc, PhD**, Senior Research Associate from Dr. Hushan Yang's lab. She was with family in Tunisia when tragedy struck. She passed away suddenly in Tunisia, Africa on August 30, 2025, after a tragic automobile accident.

As a scientist, she had a strong passion for exploration and a clear vision for career development and goals. As the lab manager, she was dependable, well-organized, and excelled in communication and outreach. As a friend, she was warm, thoughtful, talkative, and always willing to help others.

Dr. Barbirou had many clinical and research interests. From investigating novel molecular/genetic biomarkers to investigation of a novel pipeline to

isolate and characterize circulating tumor cells and liquid biopsies.

She received her PhD in Molecular Biology and Biotechnologies from the Pasteur Institute of Tunis, Tunisia in 2021. She received her Master of Science in Molecular Genetics and Biotechnologies in 2016, and her Bachelor of Science in Biology with a minor in Molecular and Cellular Biology from the Tunis El Manar University in Tunis, Tunisia.

She completed her fellowship in Cancer Genetics and Bioinformatics at the University of Missouri, School of Medicine, in Columbia, MO in 2021, and her Postdoctoral training in Molecular Oncology from Fox Chase Cancer Center, Temple University, in Philadelphia in 2022.



Thomas Jefferson University, Jefferson Health, and the Department of Medical Oncology were honored to have her as one of our own. She will be missed. Rest in Peace Mouadh.

HARIHARASUDAN MANI, MD

It is with heavy hearts that we acknowledge the sudden passing of **Hariharasudhan Mani, MD**, on November 21, 2025.

Dr. Mani completed his medical education at Thanjavur Medical College in Tamil Nadu, India.

He worked at Lehigh Valley Health Network in Allentown and Pottsville, Pennsylvania. For more than 23 years, Dr. Mani helped patients navigate the complex challenges of cancer care, with extensive clinical experience treating lung cancer, non-small cell lung cancer, and small cell lung cancer, which were central to his oncology practice. His work focused on caring for patients who required

comprehensive management and support to help maintain their quality of life during treatment. He was skilled at helping patients and their families understand treatment options and coordinate care through difficult journeys.

Dr. Mani was loved by his patients and colleagues alike. He will be remembered as cheerful, happy, empathetic, and someone who laughed out loud. He brought warmth and humanity to his work, and his presence made a meaningful difference to those around him.

He was bilingual, speaking both English and Spanish, which helped make healthcare more accessible



to diverse communities. Even after his death, Dr. Mani continues to give through his organ donations. He is survived by his wife and son.

Department of Medical Oncology

The Department of Medical Oncology brings together clinical care, research, education, and supportive oncology services across Jefferson's regional network. With leadership spanning Center City and community-based sites, the department supports a unified enterprise approach to cancer care while fostering faculty development, collaboration, inclusion, and the training of future oncology leaders.

Since its inception in 2008, the Department of Medical Oncology has evolved into one of the most diverse and integrative departments within the Jefferson Enterprise. Over the past 18 years, we have built the breadth and depth necessary to provide world-class oncologic care to our diverse patient populations, drive leading-edge research that garners national prominence, and mentor the next generation of clinical leaders. As a cornerstone of the Sidney Kimmel Comprehensive Cancer Center (SKCCC), our department remains a powerhouse of academic productivity and clinical excellence.

The department is led




William Kevin Kelly, DO, FASCO

by William Kevin Kelly, DO, FASCO, who was appointed Chair in 2023 and recently named Enterprise Chief of Cancer Services in 2025. Dr. Kelly collaborates closely with Andrew Chapman, DO, FACP, FCPP, Director,



Andrew Chapman, DO, FACP, FCPP

SKCCC and Enterprise Vice President of Cancer Research and Oncology Services, to execute the SKCCC strategic vision. Further bolstered by a strong leadership team



Maysa Abu-Khalaf, MD, MBA

consisting of Maysa Abu-Khalaf, MD, MBA, Executive Vice Chair, William Tester, MD, FACP; Vice Chair



William Tester, MD, FACP

of Clinical Operations; Janene Palidora, MHA, CSBI, Associate Vice President, Department of Medical Oncology; and Teresa Giamboy, DNP, MBA, MSN, CRNP, NEA-BC, Vice President of the Oncology Service Line.

Our footprint spans the region, including Center City, Northeast Philadelphia, Bucks County, Abington (Asplundh Cancer Pavilion), New Jersey (Cherry Hill, Stratford, and Sewell), Einstein (Philadelphia and Montgomery), and Lehigh Valley. Each regional site is led by a Vice Chair who

ensures clinical, research, and educational alignment with the enterprise mission. See figure 1 on page 8.

The Jefferson Center City campus serves as the primary academic hub, organized into five specialized divisions:

- Solid Tumor Oncology
- Hematologic Malignancies
- Bone Marrow Transplant (BMT) & Cell Therapies (TCT)
- Population Science: A unique integration that fosters high-impact collaborative research
- Supportive Oncology: A comprehensive division overseeing palliative care, social services, cancer rehabilitation, and psycho-oncology across the entire enterprise.

We are committed to workforce development through three distinct Medical Oncology/

Hematology fellowship programs:

- Our main academic campus program (in partnership with the Department of Medicine)
- The Einstein based program and
- The Lehigh Valley based program

While independent, these programs collaborate extensively, offering fellows an unparalleled diversity of clinical environments.

The department strives to be a diverse and inclusive environment, encouraging representation and participation from people of different genders, races, ethnicities, religions, ages, sexual orientations, disabilities, and classes. See figures 2 and 3 on page 9.

With two key committees, the department is dedicated to fostering an inclusive environment where faculty at all career levels can thrive.

FACULTY AFFAIRS COMMITTEE

Co-chaired by **William Tester, MD, FACP**, and **Grace Lu-Yao, PhD, MPH**,

this committee champions best practices in mentoring, work/life balance, and the promotions process. Notably, the committee utilizes bi-annual well-being surveys to support early career physicians.

MEDICAL ONCOLOGY ADVISORY COUNCIL (MOAC)

Chaired by **Lindsay Wilde, MD** (succeeding **Patrick Mille, MD**), the MOAC



Lindsay Wilde, MD

serves as a vital forum for faculty and staff voices. With representatives from every enterprise location, the Council advises leadership on recruitment, retention, and the recognition of exemplary work in clinical care and research. The Council advises department leadership on matters relating to the general welfare of the members

of the department, particularly as they relate to the ability of the faculty and staff to carry out the goals and objectives of the Department of Medical Oncology, the Sidney Kimmel Comprehensive Cancer Center (SKCCC), and Jefferson Health. The Advisory Council aims to:

- Provide a forum for faculty and staff to voice concerns about issues that impact general well-being within the department
- Periodically review enterprise policies that impact faculty and staff and provide suggestions for policy revisions
- Develop interventions aimed at improving recruitment, retention, development, and effectiveness of faculty and staff, and
- Provide department leadership with recommendations regarding recognition of faculty and staff members for exemplary work in clinical care, research, and community service

The MOAC has two clinicians from each enterprise location serve for a two-year term. They are nominated by enterprise departmental leadership to allow for clinicians of all specialties, enterprise locations, and rank to have input on departmental matters.

Figure 1: 2024 Tumor Registry Total Cases





Figure 2: Gender



Figure 3: Ethnicity



**Einstein Philadelphia and Einstein Montgomery use a separate reporting system and select data is not available. LVHN volumes are a combined total for 15 campuses. LVHN joined TJUH in 2024, select data not available.*

Select Department Highlights



Helen Evers-Hunt, MSN, RN, ONC, RN-BC, CRNP, was recognized with the **DAISY Award for Extraordinary Nurses** in January 2025. This honor celebrates nurses who demonstrate exceptional compassion, clinical excellence, and a meaningful commitment to patients, families, and colleagues.

On February 24, 2025, the Oncology Nurses raised over \$1,100 at the **Helping Hands Bake Sale**. The Helping Hands Committee is a nursing fundraiser used to assist Jefferson Health's cancer patients and their families with expenses related to costs of cancer therapies and

personal items not covered by insurance to improve quality of life. At first, these needs were quite basic, like parking passes for families traveling in daily, meals, etc. From the early inception, the fund has increased to being able to purchase plane tickets for patients and their families, holiday parties, and bill payments for families.

In April 2025, the Jefferson oncology nursing team shared their work on a national stage at the **50th Annual Oncology Nursing Society Congress** held in Denver, CO.


JoAnn Silcox, DNP, RN, CCCTM, had a poster accepted for presentation titled *Oncology Nurse Led Helping Hands Fundraiser to Support Financial Toxicity of Cancer Therapies*. The work highlighted a nurse-led effort to address the financial burden many patients experience during cancer treatment.

Additional Jefferson team members also contributed to poster presentations focused on improving patient and caregiver support.

Anne Delengowski, RN, MSN, AOCN, CCCTM,

Adam Binder, MD, and **Kristen Kriebel, RN, OCN**, presented work on an interdisciplinary approach to transitions of care.

Anne Delengowski, RN, MSN, AOCN, CCCTM, and **Caroline Glavin, SW**, also presented on a creative opportunity to support caregivers. Sheila Williams, RN, Helen Evers-Hunt, CRNP, and Noelle Fala, CRNP represented Honickman Infusion with their first ONS poster presentation, reflecting the team's continued commitment to nursing excellence, collaboration, and patient-centered oncology care.



The Center City staff came together for a **“Fly Eagles Fly” Spirit Day** for the Philadelphia Eagles’ Super Bowl LIX matchup against the Kansas City Chiefs, which took place on February 9, 2025. The group gathered in Eagles gear for a team photo, reflecting the camaraderie, energy, and community spirit shared across the department.



2025 SKMC FACULTY AWARDS

SKMC recognized its **2025 Faculty Award Winners** on June 19, 2025, celebrating outstanding faculty contributions across education, mentoring, and research. Honorees included **Marlana Orloff, MD**, **Joanne Filicko-O’Hara, MD**, and **Evan William Nardone, MD**, for Excellence in Education; **Pierluigi Porcu, MD**, for Faculty Mentoring; and **Christine Eischen, PhD**, for Research Career Achievement.



*Dean Said Ibrahim, MD, and
Marlana Orloff, MD*



*Dean Said Ibrahim, MD, and
Joanne Filicko-O’Hara, MD*



*Dean Said Ibrahim, MD, and
Evan William Nardone, MD*



*Dean Said Ibrahim, MD, and
Christine Eischen, PhD*

Joanne Filicko-O'Hara, MD, was recognized as Medical Executive President at the June 9, 2025 **Medical Executive Dinner Meeting**. This highlight reflects leadership recognition within Jefferson's medical executive community.




Joanne Filicko-O'Hara, MD (left)

The Philadelphia Gynecologic Oncology Consortium, held on July 11, 2025, brought together clinicians from across hospital systems to connect, share knowledge, and support education, networking, and collaboration in gynecologic oncology care. **Russell Schilder, MD**, and **Ida Micaily, MD** participated, with **Dr. Schilder** also presenting as part of the program.

The **3rd Annual Update on Cancer Care in Latinos, Hispanics and Latinx Communities** was held on November 1, 2025, at Thomas Jefferson University's Dorrance H. Hamilton Building in Philadelphia. The conference focused on advancing cancer care for Latino/Hispanic/Latinx communities, with sessions addressing early detection and prevention, immigrant health and ethics, research, advocacy, and team-based strategies to



Above: Drs. Micaily and Schilder at The Philadelphia Gynecologic Oncology Consortium



Right: Dr. Russell Schilder presenting on the First In-Human Phase 1a/b Study Design



Dr. Ana Maria Lopez (4th from left) at the 3rd Annual Update on Cancer Care in Latinos, Hispanics and Latinx Communities on November 1, 2025.

reduce barriers to care.

Ana Maria Lopez, MD, served as Activity/Course Director and presented on breast cancer during the Cancer Early Detection and Prevention session. The conference also included poster recognition, with awards presented for People's Choice and Best Poster/Best of Show, along with a Star Award, as part of the afternoon program.

The San Antonio Breast Cancer Symposium, held December 9–12, 2025, convened breast cancer researchers, clinicians and advocates worldwide to share the latest advances in breast cancer biology, prevention, diagnosis and treatment. Jefferson was represented through a rapid fire presentation on using electronic patient-reported outcomes and smart pill bottles to improve adherence to adjuvant endocrine therapy in early-stage breast cancer. The study, presented by **Steven A. Manobianco, MD**, included **Maysa Abu-Khalaf, MD**, among the Jefferson authors and found that smart pill bottles nearly doubled adherence odds compared with standard monitoring.

Jennifer Johnson, MD, PhD, FACP, was featured on *BackTable Tumor Board Podcast Episode #33*, Implementation &



Maysa Abu-Khalaf, MD, MBA, at SABCS (far right)

Multidisciplinary Care for Immunotherapy in Head & Neck Cancer that aired on December 15, 2025. The episode discussed integrating neoadjuvant and adjuvant immunotherapy into head and neck cancer care.


Ida Micaily, MD, presented at the **European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025** held December 10–12, 2025, in London. Her poster highlighted a Phase 1 clinical trial of BHV-1510, a next-generation Trop2 antibody-drug conjugate, in combination with Cemiplimab for patients with advanced solid tumors, and it was also featured on the poster for the event. Her participation reflected Jefferson's engagement in international oncology research and emerging treatment approaches in immuno-oncology.



Steven A. Manobianco, MD, presenting at the San Antonio Breast Cancer Symposium



Jennifer Johnson, MD, PhD, FACP, as featured on BackTable Tumor Board podcast



Ida Micaily, MD, with her poster highlighting a Phase 1 clinical trial of BHV-1510

Faculty excellence was recognized once again in 2025, with 30 faculty members across the enterprise named Philadelphia Magazine "Top Doctors" on May 1st. This recognition reflects the strength of the department's clinical expertise and its continued commitment to nationally recognized cancer care throughout the Greater Philadelphia region and Southern New Jersey.



Maysa Abu-Khalaf, MD



Willard Andrews, MD



Rita Axelrod, MD



Babar Bashir, MD



Attrayee Basu Mallick, MD



Avnish Bhatia, MD



Adam Binder, MD



Marcia Brose, MD, PhD



Steven Cohen, MD



Kathleen C. Degan, MD



Claudia Dourado, MD



Tracey Evans, MD



Frederick Fellin, MD



Andres Ferber, MD



Eduardo Fernandez, MD



Christian J. Fidler, MD



Joanne Filicko-O'Hara, MD



Mitchell Goldstein, MD



Margaret Kasner, MD



Wm. Kevin Kelly, DO



John C. Leighton, Jr., MD




Ana Maria Lopez, MD



Mark Morginstin, DO



Melanie Nordlinger, MD



Pierluigi Porcu, MD



Michael Ramirez, MD



Joanna Rodriguez, MD



Russell Schilder, MD



William Tester, MD




Allison Zibelli, MD

Clinical Achievements

The Clinical Pillar reflects steady enterprise-wide growth in patient volume and continued expansion of advanced oncology services. With rising new, existing, and infusion patient volumes, growth in BMT/TCT procedures, new clinical trials, and planned program expansion, the department is strengthening access, innovation, and patient-centered cancer care across the Jefferson enterprise.

Our Jefferson team has steadily increased patient volume over the past three fiscal years across the enterprise. A breakdown for new patient volume is shown in figure 4 below, existing patient volume is shown in figure 5 and infusion patient volume is shown in figure 6, both on page 16.

Figure 4: New Patient Volume



*Einstein Philadelphia and Einstein Montgomery use a separate reporting system and select data is not available. LVHN volumes are a combined total for 15 campuses. LVHN joined TJUH in 2024, select data not available.

Figure 5: Existing Patient Volume





Figure 6: Infusion Patient Volume



**Einstein Philadelphia and Einstein Montgomery use a separate reporting system and select data is not available. LVHN volumes are a combined total for 15 campuses. LVHN joined TJUH in 2024, select data not available.*


Research Achievements

The Research Pillar reflects the Department of Medical Oncology's growth as a leading academic and clinical research enterprise. Over the past decade, the department has increased external research funding while strengthening endowments, philanthropy, clinical trials, and scholarly output. This momentum advances cancer research, expands trial access, fosters collaboration, and supports discovery and improved patient outcomes.

GRANTS

The Department of Medical Oncology has had a major focus on externally funded research expenditures over the past five fiscal years as evidenced by the growth since fiscal year 2020.


Figure 7: Total Actual Costs Received Based on Expenditures



ENDOWMENTS

As shown in figure 8, endowments in the Department of Medical Oncology have steadily increased year over year for the past three years.


Figure 8: Endowments



PHILANTHROPIC FUNDS

Across the enterprise, the Department of Medical Oncology has brought in an average of \$2,759,960 each year in philanthropic funds. Figure 9 shows the five year breakdown.


Figure 9: Philanthropic Funds



CLINICAL ACCRUALS

The Sidney Kimmel Comprehensive Cancer Center supports clinical trials at five of our sites: Jefferson—Abington and Asplundh Cancer Pavilion, Jefferson—Methodist Hospital, Jefferson—Northeast at Torresdale Hospital, Sidney Kimmel Comprehensive Cancer Center in Washington Township and Thomas Jefferson University Hospital.

Figure 10: Clinical Accruals by Site FY21 – FY25



Educational Achievements

The Education Pillar highlights the Department of Medical Oncology's broad commitment to training through UME, GME, and CME. With bedside teaching, didactic learning, research mentorship, fellowship training, enterprise-wide faculty involvement, and JeffMD support, the department prepares future oncology leaders through clinical, academic, and research-based education.

Active medical education programs in the Department of Medical Oncology span undergraduate medical education (UME), graduate medical education (GME), and continuing medical education (CME). There is a commitment to outstanding education that includes both clinical "at the bedside" teaching, didactic conference-based learning, and research education.

UME includes:

- **Phase I Learning** under the direction of **Marlana Orloff Dacey, MD**, and includes a focus on "Blood and Host Defense"
- **Phase 2 Learning** in clinical clerkships with multiple faculty members covering the four Blue Medicine services through out the year
- **Phase 3 Learning** including sub internships on the Blue Medicine services, as



The Sidney Kimmel Medical College Class of 2025 celebrates the end of Phase One

well as electives in solid tumor inpatient consults, outpatient electives in solid tumor and hematologic malignancies, and bone marrow transplant.

Medical students have opportunities to do clinical research with our faculty members as

well, from learning the process of submitting Institutional Review Board (IRB) paperwork through submitting manuscripts for publication.

The department's GME effort includes the Fellowship in Hematology and Medical Oncology, accredited by the Accreditation Council

for Graduate Medical Education (ACGME). The fellowship is a joint effort with the Division of Hematology in the Department of Medicine. It is approved for up to 24 fellows, usually having 6-7 fellows per year. Most fellows pursue training in both hematology and medical oncology. Fellows do 18-24 months

of clinical time with the second half of fellowship tailored toward career goals, including more clinical time, basic or clinical research. All fellows are required to complete “scholarly work” and are mentored by faculty to produce presentations, clinical research protocols, and manuscripts. In the last five years, 39% of fellows have gone on to academic careers, 36% have gone into general practice, 9% have chosen a hybrid between academic and general practice, and 6% have gone into the pharmaceutical industry. 19% have stayed within the

Jefferson Health System. The Hematology and Medical Oncology Fellowship program at Einstein Medical Center in Philadelphia proudly accepted its first fellow in the 2014-2015 academic year. The fellowship program is a three-year ACGME-accredited, clinically oriented program that accepts two fellows per year. Jefferson Einstein Philadelphia Hospital and Jefferson Einstein Montgomery Hospital have extremely busy inpatient and outpatient services which allow for broad exposure to a wide variety of diseases and diverse patient populations, ensuring a well-rounded

learning experience. Our program has a board passing rate of 100% on first attempt for hematology and medical oncology. Fellows that graduated our program have joined renowned academic institutions and large private practices.

The GME effort also includes mentorship of the internal medicine residents. Similar to UME, this includes clinical teaching on the Blue Medicine services, on consult services, and in the Bone Marrow Transplant unit. It includes both inpatient and outpatient experiences. Faculty provide didactic conferences and

mentorship for clinical research projects.

CME is intertwined with the efforts of the SKCCC and includes multiple recurring conferences throughout the year. These include tumor boards and research conferences, in addition to symposia on various cancer related topics.

The Department of Medical Oncology faculty includes physicians at multiple enterprise sites. While the main efforts for UME and GME are based at the Center City campus, the faculty at the other sites are also heavily involved in education at all levels. There

Figure 11: Graduates of the Jefferson Fellowship Program and the Institution They Joined After Graduation

CLASS OF 2019	
Graduate	Institution
Babar Bashir, MD	SKCCC, Jefferson Health—Center City Division of Solid Tumor, Philadelphia, PA
Aileen Deng, MD	Novant Health Lake Norman Oncology, Mooresville, NC
Roberto Fratamico, MD	Lehigh Valley Hematology Oncology, Allentown, PA
Evan Lapinsky, MD	Medical Oncology Hematology Associates, Christiana, DE
Lillian Man, MD	Lapidus Cancer Institute at Sinai Hospital, Baltimore, MD
Amy McGhee-Jez, MD	Medical Oncology Hematology Associates, Christiana, DE
Ruben Rhoades, MD	Sidney Kimmel Medical College, Jefferson Health, Cardeza Foundation for Hematologic Research, Philadelphia, PA
Adetokunbo Oluwasanjo (Toks), MD	Florida Cancer Specialists, Lake City, FL
CLASS OF 2020	
Graduate	Institution
Kim Aderhold, DO	Hematology Oncology, Tower Health Medical Group, Reading, PA
Dan Altman, MD	Abramson Cancer Center, Chester County Hospital, West Chester, PA
William Johnson, DO	Memorial Sloan Kettering Cancer Center, New York, NY
Gina Keiffer, MD	SKCCC, Jefferson Health—Center City Division of Hematologic Malignancies, Philadelphia, PA
Amanda McBride, MD, PhD	Research Year at Incyte Corporation, Wilmington, DE
Maria Vershovsky, MD	Abramson Cancer Center, Chester County Hospital, West Chester, PA

CLASS OF 2021

Graduate	Institution
Sushil Ghimire, MD	MD Anderson Cancer Center at Cooper, Camden NJ
Kevin Hou, MD	Jefferson Abington Hospital, Abington, PA
Teresa Lee, MD, PhD	Fox Chase Cancer Center, Philadelphia, PA
Jonathan Pan, MD	MD Anderson Cancer Center at Cooper, Camden NJ
Sabrina Ramanathan, MD	Texas Oncology, Sugar Land, Sugar Land, TX
Kelsey Sokol, MD	Bennett Cancer Center, Stamford CT

CLASS OF 2022

Graduate	Institution
Abdullateef Abdulkareem, MD	Ann B. Barshinger Cancer Institute, Lancaster, PA
Xia Bi, MD	SKCCC, Jefferson Health—Center City Division of Transplant-Cellular Therapy (T-CT), Philadelphia, PA
Victor Bilan, MD	Hematology & Oncology Assoc., UPMC Hillman Cancer Center, Pittsburgh, PA
Ranju Kunwor, MD	Saint Louis University, Bone Marrow Transplant & Cellular Therapies Program, St Louis, MO
Ida Micaily, MD	SKCCC, Jefferson Health—Center City Division of Solid Tumor, Philadelphia, PA
Zachary Quinn, MD	SKCCC, Jefferson Health—Center City Division of Solid Tumor, Philadelphia, PA
Christopher Terry, MD	Sturdy Memorial Associates in Attleboro, MA

CLASS OF 2023

Graduate	Institution
Molly Halloran, MD	Incyte Corporation, Wilmington, DE
Sarah Houtmann, MD	Abramson Cancer Center, Chester County Hospital, West Chester, PA
Yasir Khan, MD	Southern Hematology Oncology Associates, Vineland, NJ
Daniel Lefler, MD	Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Colin Thomas, MD	Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

CLASS OF 2024

Graduate	Institution
Monica Adedeji, MD, MPH	Northwestern Medicine, Geneva, IL
Aditya Eturi, MD	Tower Health, Solid Tumor, West Reading, PA
Zachary French, MD	Jefferson Cherry Hill Hospital, Cherry Hill, NJ
Andrew Iskandar, MD	Jefferson Cherry Hill Hospital, Cherry Hill, NJ
Chetan Jeurkar, DO	SKCCC, Jefferson Health—Center City Division of Hematologic Malignancies, Philadelphia, PA
Aditya Kulkarni, MD	Cooperman Barnabas Medical Center, Livingston, NJ
Shaik Abdul Samad Shaik Abdul Rashid Samad Rashid, MD	Geisinger Wyoming Valley, Wilkes Barre, PA

CLASS OF 2025

Graduate	Institution
Umair Atiq, MD	Reading Hospital Hematology Oncology, Phoenixville, PA
Matt Bloom, MD	Tampa General Hospital Cancer Institute, Tampa, FL
Quinto Gesiotto, MD	Tampa General Hospital Cancer Institute, Tampa, FL
Steven Manobianco, MD	SKCCC, Jefferson Health—Center City Division of Solid Tumor, Philadelphia, PA
Rebecca Masel, MD	Jefferson Abington Hospital and Asplundh Cancer Pavilion, Abington, PA

are medical students from the SKCCC who rotate at the other sites and students from other local medical schools who rotate with our faculty (e.g. Cooper Medical School-Rowan University and Jefferson Washington Township Hospital, Jefferson Cherry Hill Hospital, and Jefferson Stratford Hospital). There are internal medicine and family medicine residencies at Jefferson

Hospital Abington, Jefferson Torresdale Hospital, Jefferson Einstein Philadelphia Hospital, Jefferson Einstein Montgomery Hospital, Jefferson Washington Township Hospital, Jefferson Cherry Hill Hospital, and Jefferson Stratford Hospital. These residents will manage inpatients with our faculty and have the opportunity to do outpatient electives.

The CME effort includes programs at the other sites, including a SKCCC–Jefferson Health Oncology Grand Rounds.

The faculty of the Department of Medical Oncology provide a broad spectrum of educational experiences that are both clinical and non-clinical, experiential and didactic, practical and research based, encompassing UME, GME

and CME. See figure 11 on pages 22-24.

Physicians who teach at the Sidney Kimmel Medical College and support the JeffMD program are shown in figure 12 below alongside the courses they teach.

Figure 12: Physicians Who Teach at SKMC and Support the JeffMD Program

Physician	Program Block	Role
Melissa DiCarlo, PhD, MPH, MS	Scholarly Inquiry	Associate Director
Amy Leader, DrPh, MPH	Scholarly Inquiry	Mentor
Patrick Mille, MD	Clinical Skills Small Group	Leader
Evan Nardone, MD	Clinical Skills Small Group	Leader
Evan Nardone, MD	Phase 3	Gateway Small Group
Marlana Orloff Dacey, MD	Phase I	Block Director
Brooke Worster, MD	Scholarly Inquiry	Mentor
Lindsay Wilde, MD	Phase 3	Av Basic Science Director

Education Programs

The Department of Medical Oncology maintains education programs across UME, GME, and CME, combining clinical teaching, didactic learning, and research education. Medical students, residents, and fellows participate in clerkships, fellowships, mentorships, and scholarly activities. Educational efforts extend across Jefferson sites, reflecting an enterprise-wide commitment to medical education.

The Department of Medical Oncology has active medical education programs in UME, GME, and CME. We have a commitment to outstanding education that includes clinical “at the bedside” teaching, didactic conference-based learning, and research education.

UME includes didactic lectures and small group sessions as part of the JEFFMD Phase I Curriculum and clinical clerkships with multiple faculty members as part of the Phase 2 Curriculum. Phase 3 of JEFFMD includes options for sub internships on the Blue Medicine services, as well as electives in solid tumor inpatient consults, outpatient electives in solid tumor and hematologic malignancies, and transplant and cellular therapy. Medical students also have opportunities to do clinical research with our faculty members, from learning how to submit IRB paperwork to submitting manuscripts for publication.

At the GME level, the combined Hematology/Oncology Fellowship at Thomas Jefferson University Hospital is a joint effort between the Department of Medical Oncology and the Division of Hematology in the Department of Medicine.

There are, on average, six fellows per year in the three-year program. Fellows complete 18-24 months of clinical work in the first part of their training, with the second part tailored toward academic work and preparation for their future career. All fellows participate in scholarly activity and are mentored by faculty to develop research projects, educational presentations, clinical trial protocols, and manuscripts. During the 2024-2025 academic year, the fellows produced 15 peer-reviewed publications, 14 abstracts, six invited lectures, and two successful grant submissions.



2025 Graduating Fellowship Class

In the last five years, 45% of fellows have gone on to academic careers, 21% have gone into community-based practice, 31% have chosen a hybrid between academic and general practice, and 3% have gone into the pharmaceutical industry. Twenty-eight percent (28%) of graduates have remained at Jefferson Health. See figure 13 on the next page.

The Hematology and Medical Oncology

Fellowship program at Einstein Medical Center Philadelphia is a separate program, a three-year ACGME-accredited, clinically oriented program that accepts two fellows per year. Jefferson Einstein Philadelphia Hospital and Jefferson Einstein Montgomery Hospital have busy inpatient and outpatient services, allowing broad exposure to various diseases and diverse patient populations, ensuring a well-rounded

2024-2025 Fellowship Class




Alexis Bennett, MD
PGY4



Akshit Chitkara, MD
PGY4




Sohail Deshpande, MD
PGY4



Emily Hansinger, MD
PGY4



Pavan Patel, MD
PGY4



Nicholas Schmedding, MD
PGY4




Fahad AlKaabba, MD
PGY5



Ian Landry, MD
PGY5



Tara Rakiewicz, MD
PGY5




Sean Reilly, MD
PGY5



Ali Raza Shaikh, MD
PGY5




Sameep Thapa, MD
PGY5




Yang Yang, MD
PGY5




Muhammad Umair Atiq, MD
PGY6



Matthew Bloom, MD
PGY6



Quinto Gesiotto, MD
PGY6



Steve Manobianco, MD
PGY6



Rebecca Masel, MD
PGY6



Fellowship 2025 Journal Club

learning experience. Fellows who graduated from the Jefferson program have gone on to practice at both academic institutions and private practices.

The GME effort also includes mentorship of internal medicine residents. Similar to UME, this includes clinical teaching on the Blue Medicine services, consult services, and in the Bone Marrow Transplant Unit. It includes both inpatient and outpatient experiences. Faculty provide didactic conferences and mentorship for clinical research projects.

CME is intertwined with the efforts of the Sidney Kimmel Comprehensive Cancer Center and


includes multiple recurring conferences throughout the year. These include tumor boards, research conferences, and symposia

on various cancer-related topics.

This year, the department held our inaugural **Updates in Medical Oncology**

Symposium. It was a well-attended CME event for clinicians in the Jefferson enterprise, and was developed through

Figure 13: Career Distribution 2021–2025



the efforts of a steering committee including physician representatives from throughout the enterprise (Drs. Fernandez, Fidler, Gupta, Tester, Wysota). The steering committee continues to meet and has planned the next symposium for May 2026, in addition to starting a monthly Medical Oncology Grand Rounds series to start in the next academic year.

The Department of Medical Oncology faculty includes physicians at multiple

enterprise sites. While the main efforts for UME and GME are based at the Center City campus, the faculty at the other sites are also heavily involved in education at all levels. There are medical students from the Sidney Kimmel Medical College (SKMC) who rotate at the other sites and students from other local medical schools who rotate with our faculty (e.g., Cooper Medical School—Rowan University at Jefferson Washington Township

Hospital, Jefferson Cherry Hill Hospital, and Jefferson Stratford Hospital offices). There are internal medicine and family medicine residencies at Jefferson Abington Hospital, Jefferson Einstein Philadelphia Hospital, Jefferson Washington Township Hospital, Jefferson Cherry Hill Hospital, and Jefferson Stratford Hospital. These residents will manage inpatients with our faculty and have the opportunity to do outpatient electives.

The CME effort includes programs at the other sites, including SKCCC—Jefferson Health Oncology Grand Rounds.

In summary, the faculty of the Department of Medical Oncology provides a broad spectrum of educational experiences that are both clinical and non-clinical, experiential, and didactic, practical, and research-based, and encompass UME, GME, and CME.

Quality Achievements

The oncology service line established a three-year quality strategic plan to guide alignment, improvement, and delivery of patient-centered cancer care across SKCCC. The plan is anchored in the ACES model—Access, Care Engagement, and Support—and outlines priorities to strengthen care delivery, coordination, and innovation.

In February 2025, the Oncology Quality Officers, **Adam Binder, MD**, and **Valerie Csik, MPH, CPPS**, developed a three-year Quality Strategic Plan to outline key priorities to drive alignment and improvement. The plan outlines the mission of the SKCCC Oncology OnPoint Team. Our goal is to create an aligned care delivery model that provides high quality care, comprehensive patient support, and leads clinical innovation to position the oncology service line as a national leader in delivery of patient-centered cancer care.

Guiding the work of the Oncology OnPoint Council is the ACES Model focused on Access, Care Engagement, and Support. Alignment of these components is what will guide development of our patient-centered cancer care delivery model. (figure 14)

Figure 14: ACES Model




Figure 15: Oncology OnPoint Quality Dyads

Location	Clinical Lead	Administrative Lead
Jefferson Hospital Abington	Colleen Erb	Molly Schwartz
Thomas Jefferson University Hospital	Adam Bnder	Ashley Miles
Jefferson Einstein Montgomery Hospital	Mitchell Goldstein	Jill Ranochak
Jefferson Einstein Philadelphia Hospital	John Leighton	Amanda Liegel-Held
Jefferson Torresdale Hospital	Vladimir Limonnik	Kelli Sherwin
JNJ	Anthony Scarpaci	Alyson Seiden
LV	Melissa Kratz	Savitri Skandan

The Oncology OnPoint Team, led by service line quality officers and supported by a team of quality leads, is working toward these goals. The quality leads serve as local champions at their care delivery site to execute and sustain strategies to drive improvement. (figure 15)

To begin to align the oncology service line around these focus areas, a vision statement was developed to guide our work.

VISION STATEMENT

At the SKCCC, we are committed to delivering timely and efficient care that is guided by individual patient wishes, innovative therapy, and multidisciplinary care.

- We work in collaborative teams to enhance the patients quality of life both during and after treatment.
- Our care teams listen with intention, respond with empathy, act with compassion, and

provide holistic support to patients and their families.

- Our clinicians develop treatment plans and make decisions that incorporate the dignity, voice, and well-being of those we care for.

WHERE WE’VE BEEN: FY25 ACCOMPLISHMENTS

CARE DELIVERY IMPACT

In comparison to fiscal year 2024:

- 22% decrease in 30 day readmissions across the enterprise.
- 10% increase in seven day follow-up in oncology.
- 37% increase in health related social needs (HRSN) screening completion.
- Strong performance across the enterprise with targets met across all four quality metrics: 30 day readmissions, seven

day follow-up, HRSN completion and mortality.

The following strategies were executed:

- New protocols for patients receiving certain inpatient elective chemotherapy regimens decreased length of stay from five to three days. Early ambulation pilot program to improve rates of discharge to home and reduce in hospital falls was initiated in Center City.
- Mortality reviews and documentation strategies have supported a significant reduction in the enterprise mortality rate from 1.03 to 0.92 for SKCCC patients. At Thomas Jefferson University Hospital (TJUH), the mortality index has been steadily decreasing over the last two years and was 0.45 in FY25.

- An outpatient sepsis protocol was developed to improve timeliness of treatment and adherence to guideline concordant care for people presenting to the cancer center with concern for sepsis.
- The order set was piloted in Center City, resulting in a five-day reduction in length of stay and a decrease in intensive care unit admissions from 14% to 3%.

The protocol and workflows have been scaled across the enterprise and outcomes are being monitored closely.

As part of the American Society of Hematology Quality Improvement Training Initiative (ASHI QITI), an interprofessional team completed an 18 month intensive quality improvement training program and implemented an initiative to decrease the

Figure 16: Fiscal Year 2026 Priorities

MEASURE	MEASURE DEFINITION	WHY IT MATTERS
30 Day Readmissions	Inpatient adult discharges from an oncology sub-service line who return within 30 days of their admission to another inpatient stay, mimics National Quality Forum endorsed all cause oncology readmissions criteria.	Poor care transitions are the result of inadequate information being shared when a patient transitions from the hospital to home and often result in readmissions. Avoiding readmissions is a signal of good quality care transitions.
HRSN Outreaches	Patients that have a documented social work outreach following a positive health related social needs (HRSN) assessment (high risk) among patients in active cancer treatment.	Identifying and removing barriers to care is critical to ensuring timely cancer treatment.
Time to Treatment - Breast Cancer	Time from diagnosis to cancer treatment initiation (surgery, chemotherapy, radiation, oral chemotherapy). Time from diagnosis to surgery should be within 30 days according to National Comprehensive Cancer Network (NCCN) guidelines and NAPBC. This metric will evaluate cases where diagnosis to surgery exceeds 30 days. Time from diagnosis to chemotherapy should be within 60 days according to NCCN guidelines, National Accreditation Program Breast Centers (NAPBC) and Commission on Cancer (CoC). This metric will evaluate cases where diagnosis to chemotherapy exceeds 60 days.	Timely access to cancer treatment improves prognosis.
Admission and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy	One or more ED visits OR inpatient admissions for any of the following 10 diagnoses—anemia, dehydration, diarrhea, emesis, fever, nausea, neutropenia, pain, pneumonia, or sepsis—within 30 days of chemotherapy treatment of active cancer patients who received at least one outpatient chemotherapy treatment during the last year.	Effective symptom management improves patient quality of life and impacts acute care utilization.
Likelihood to Recommend	Patient experience feedback for patients undergoing cancer treatment i.e. Oncology Survey.	Direct patient feedback on their experience while receiving treatment.

the time to transfer for people with aggressive hematologic malignancies.

The impact was significant. Transfer time was reduced from 18 hours to six hours.

This work led to four abstracts presented at national meetings (two of which were oral presentations), one peer reviewed manuscript, and three manuscripts currently in progress.

WHERE WE'RE GOING: FY26 PRIORITIES

In March 2025, an annual retreat was held to bring together the Oncology OnPoint Team to identify priorities for the year

ahead. The focus for FY26 is a transition from process to outcomes-driven metrics. Through a review of nationally recognized oncology metrics and discussion, the following priorities were identified for FY26. See figure 16 on the previous page.

A communication strategy was executed at the start of the fiscal year to raise awareness of these metrics and their importance. Throughout this fiscal year, our quality leads will continue to monitor these metrics and take action locally to drive improvement.

The scope of this work is at the service line level and currently includes Medical

and Radiation Oncology.

It is our hope that we will strengthen engagement this year and begin to identify sub-specialty relevant metrics to continue making progress toward better aligned patient-centered cancer care for all SKCCC patients.

CENTER CITY PHILADELPHIA

Division of Solid Tumor Oncology

The Solid Tumor Division reflects a comprehensive, disease-specific approach to cancer care, research, education, and community engagement. With 22 faculty across multiple subspecialties, the Division advances patient-centered care through inpatient and outpatient services, nationally recognized Phase I trials, research, multidisciplinary clinics, collaboration, philanthropy, outreach, and training.

The Solid Tumor Division is comprised of 22 faculty members who are dedicated to academic research, clinical trials, and disease-specific clinical care. They provide outpatient and inpatient services for various types of solid tumors, including those affecting the gastrointestinal, genitourinary, head and neck, thoracic, skin (including melanoma), soft tissue, bone, gynecological, and breast areas.

This division is organized into teams, each specializing in a subspecialty of solid tumors. Each team has a leader who focuses on collaborating with basic and translational scientists to develop a clinical trial portfolio. The teams also work closely with advanced care hubs throughout the enterprise in medical oncology. The faculty members actively engage in collaboration with medical oncology from advanced care hubs offering direct

guidance and support for complicated and rare cases.

In 2023 the regional cancer care division members joined the solid tumor division to further integrate care delivery between the Center City and Methodist campuses.

On June 9, 2025, **Jennifer M. Johnson, MD, PhD, FACP** was promoted to Professor




Jennifer M. Johnson, MD, PhD, FACP



Daniel Lin, MD

and **Daniel Lin, MD, MSc**, was promoted to Associate Professor.

Steven Manobianco, MD, joined our Solid



Steven Manobianco, MD

Tumor Division as a breast oncology attending on August 1, 2025, bringing specialized experience in comprehensive breast cancer treatment.



Khvaramze Shaverdashvili, MD, PhD

FACULTY

Atrayee Basu Mallick, MD

*Associate Professor
Director, Division of Solid Tumor*



Maysa Abu-Khalaf, MD, MBA

*Professor
Chief, Cancer Services*

Vitali Y. Alexeev, PhD

Assistant Professor

Nadezhda Anikeyeva, PhD

Instructor

Rita Axelrod, MD

Professor

Babar Bashir, MD

Associate Professor

Claudia Capparelli, PhD

Assistant Professor

Sarah Gordon, DO

Associate Professor

Jennifer M. Johnson, MD, PhD, FACP

Professor

Daniel Lin, MD, MSc

Associate Professor

AnaMaria Lopez, MD, MPH, MACP

Professor

Steven Manobianco, MD

Assistant Professor

Ida Micaily, MD

Assistant Professor

Patrick Mille, MD

Assistant Professor

Marlana Orloff, MD

Associate Professor

Michael Ramirez, MD

Assistant Professor

On December 1, 2025, **Khvaramze Shaverdashvili, MD, PhD**, joined us as an assistant professor, with a clinical and research focus on head, neck, and lung cancers.

CLINICAL

The focal point of all activities is the provision of state-of-the-art clinical care. The service is structured around a disease-specific care team model. Apart from regular medical oncology clinics, clinical care is also extended through the implementation of Multidisciplinary Clinics (MDC) in all subspecialties. In these clinics, patients have the opportunity to meet with medical oncologists, surgeons and radiation oncologists in the same setting. This setup aims to streamline

real-time multidisciplinary care, particularly in complex cases, and offers the convenience of a single visit to consult with multiple clinicians.

RESEARCH

The solid tumor faculty actively engage in a spectrum of clinical trials, encompassing investigator-initiated, cooperative group, and industry-sponsored trials spanning from Phase I to Phase III. Our Phase I trial program is distinguished nationally, with over 45 active trials at any given time, including first-in-human trials in solid tumors. This has positioned us as a referral center for the tristate area.

Beyond clinical research, faculty members are actively involved in basic

and translational research, boasting over 14 active grants within the division, including R01 grants from National Institutes of Health (NIH) and the Department of Defense (DoD).

EDUCATION

The faculty actively participates in the education of medical students, residents, and hematology and oncology fellows. This involvement encompasses both outpatient and inpatient clinical settings. They also deliver didactic lectures on a scheduled basis.

COMMUNITY OUTREACH

In 2025, our faculty have taken the lead in initiating and chairing more than 15 symposiums, cancer walks, screening events,

FACULTY

Takami Sato, MD
Professor

Rino Seedor, MD
Assistant Professor

Khvaramze (Khako) Shaverdashvili, MD, PhD
Assistant Professor

Daniel Silver, MD, PhD
Professor

Yuri Selyukov, MD, PhD
Professor

Mizue Terai, PhD
Assistant Professor

William Tester, MD, FACP
Professor

Irina A. Vasilevskaya, PhD
Instructor, Head & Neck

Kevin Kayvan Zarrabi, MD, MS, FACP
Assistant Professor

Allison Zibelli, MD
Assistant Professor

INFUSION SAME DAY CLINICIAN

Helen Evers-Hunt, MSN, RN, ONC, RN-BC, CRNP

SAME DAY NEXT DAY ADVANCED PRACTICE CLINICIANS

Amy Karman, PA-C
Courtney Scott, CRNP
Tintu George, CRNP

ADVANCED PRACTICE CLINICIANS

Pashara Arties, CRNP
Marleah DiMenna, CRNP
Noelle Fala, CRNP
Jessi Falcone-Lupinacci, CRNP
Amanda Emily Jackson, CRNP
Emily Matey, CRNP
Madeline Naccarato, CRNP
Erin Sharpe-Mills, CRNP
Miranda Tsang, CRNP
Arin Weiss, CRNP
Cynthia Wheeler, CRNP



A portrait unveiling ceremony of Dr. Takami Sato, the Director of Metastatic Uveal Melanoma Program. This portrait marks Jefferson's first portrait honoring an Asian American.

and talks within the SKCCC catchment area. These events cover a range of topics related to specific cancers, diversity, inclusion, and community engagement.

PHILANTHROPY

More than \$3 million in philanthropic gifts were received in 2025, reflecting meaningful support for the department's clinical, research and academic missions. Numerous faculty members were honored through philanthropy awards and endowed recognitions, including **Marlana Orloff Dacey, MD**, who was recognized as the Alexander and Johnston Family Endowed Clinical Director of Uveal Melanoma, an endowed position supporting her clinical and research focus on primary and advanced melanomas, including rare melanoma subtypes.

FUTURE PLANS

- **Strategic Leadership Transition:** Implement a smooth leadership transition with the departure of key personnel, ensuring continuity and sustained excellence in patient care, research, and education.
- **Specialized Recruitment:** Actively recruit and appoint experts in various solid tumor subspecialties



Left to right: Mizue Terai, PhD, Carin Gonsalves, MD, Marlana Orloff Dacey, MD, David Eschelmann, MD, and Takami Sato, MD at the Investiture Ceremony of Marlana Orloff Dacey, MD.

- enhancing the division's capabilities and expanding its range of expertise.
- **Enhanced Clinical Services:** Further develop and optimize clinical services through the continued growth of multidisciplinary clinics, offering comprehensive and streamlined care for patients with solid tumors.
- **Advanced Clinical Trials:** Strengthen the focus on clinical trials, including investigator-initiated, cooperative group, and industry-sponsored trials. Emphasize Phase I trials, solidifying our position as a national referral center.
- **Research Expansion:** Expand research endeavors and collaboration between clinical and research faculty through Molecular Oncology Regulation and Approaches (MORA), Translational and Cellular Oncology (TaCO), and Immune Regulation and Targeting (IRT) programs within SKCCC. Seek additional grant funding to support ongoing and new research initiatives within the division.
- **Community Engagement:** Increase community engagement through the organization of symposiums, cancer walks, screening events, and talks. Address topics related to specific cancers, diversity, inclusion, and community health.
- **Philanthropy and Funding:** Continue to actively pursue philanthropic initiatives to secure additional funding for the division's growth and sustainability
- **Enterprise-wide Collaboration:** Foster collaboration with other departments and advance care hubs across the enterprise to enhance subspecialty care and ensure a holistic approach to patient well-being.

- **Clinical Trial Office (CTO) Collaboration:**

Work closely with the Clinical Trial Office to streamline processes and increase trial accrual, ensuring that the division remains

at the forefront of innovative treatments.


- **Outreach and Referral Programs:** Expand outreach activities to increase referrals to Phase I programs

and other specialized services, strengthening partnerships with referring physicians and healthcare institutions.

By focusing on these strategic initiatives, the Solid

Tumor Division is poised to not only maintain its current standards of excellence, but also achieve sustainable growth and advancement in patient care, research, and education. (figure 17)

Figure 17: 2024 Center City Philadelphia Top Five Cases



Hospitalists

The Oncology Hospitalist Section within the Division of Solid Tumor plays a vital role in the care of solid tumor oncology patients admitted to Thomas Jefferson University Hospital in Center City. Through teaching services staffed by faculty, residents, nurse practitioners, and rotating medical students, the section provides high-value inpatient oncology care while creating a strong educational experience for learners. Its work reflects a commitment to multidisciplinary collaboration, clinical quality, documentation excellence, patient safety, and continuous improvement across inpatient oncology services.

The Medical Oncology Hospitalist Section within the Division of Solid Tumor oversees inpatient admissions for solid tumor oncology patients at Thomas Jefferson University Hospital in Center City.

There are four faculty members who staff two teaching services with internal medicine residents. Sidney Kimmel Medical College students also rotate on the service as part of their core medicine rotation. Learners are exposed to valuable, high-yield inpatient solid tumor oncology cases, including febrile neutropenia, chemotherapy side effects, bloodstream infections, cancer-related pain, malignant cord compression, and end-of-life care with hospice transitions.

Additional inpatient oncology services include:

- Bone Marrow Transplant, which is also co-managed by BMT hospitalists and hematology malignancy oncologists.
- The Leukemia/Lymphoma service, staffed by hematologists, includes house staff as part of its inpatient care team.
- There are six inpatient nurse practitioners who oversee elective chemotherapy admissions along with rounding oncologists.

Hospitalists play a vital role in managing inpatient care for solid tumor oncology patients. The inpatient oncology services, Blue 3 and Blue 4, are very popular house staff rotations, with

high satisfaction reported among those caring of cancer patients.

HIGHLIGHTS

Some of the highlights of oncology hospitalists from 2025 include:

- **Min Woo Hwang, MD, MBA** joined us in July 2025 from Inova Fairfax Medical Campus
- All teaching service with high emphasis on education for learners
- The service is one of the oldest at TJUH to maintain daily in-person multidisciplinary rounds with oncology nurse managers, charge nurses, case managers, physical therapists, and pharmacists.
- Over the past year, hospitalists have adopted problem-

FACULTY

Suchit Bhutani, MD

*Assistant Professor
Lead Hospitalist*



Boula Gattas, MD

Instructor

Rachel Grosso, MD

Assistant Professor

Min Woo Hwang, MD, MBA

Instructor

Jiahui Jiang, MD

Instructor

Evan Nardone, MD

*Assistant Professor
Clinical Educator*

Arpona Dev Nath, MD

Instructor

Emma Weaver, MD

*Assistant Professor
Clinical Educator*

ADVANCED PRACTICE CLINICIANS

Alizabeth M. Berry, PA-C
Kate Clancy, CRNP
Katie Fendler, CRNP
Patty Galanis, DNP, CRNP
Regine Nshimiyimana-Maniraho, DNP, CRNP
Jen Rauscher, CRNP

based note writing, making notes easier to review and more useful for coding.

- Hospitalists have consistently met target metrics set by the Hospital Medicine Council, like utilization of discharge milestones and use of event reporting.
- The group has begun using documentation that captures comorbidities, including Elixhauser variables, which are among the measures tracked by *U.S. News & World Report*.
- The hospitalist group has revived the

Department of Medical Oncology Mortality Review Committee after a pause over the past few years.

- Section Lead Oncology Hospitalist, **Suchit Bhutani, MD**, is a member of TJUH Hospital Medicine Council.
- **Evan Nardone, MD**, received numerous teaching awards from house staff last year including Oncology Service Attending of the Year Award.
- **Dr. Bhutani**, serves as core faculty for the internal medicine residency program. He is involved in the

Core Competency Residency Committee and the recruitment of residency candidates. He also participates in morning report for residents.

- **Emma Weaver, MD**, is a member of the Oncology Physician Advisory Committee.
- The group participated in its first hospitalist-led inpatient clinical trial, *Evaluating the Feasibility of an ePRO System Among Newly Discharged Cancer Patients: ePRO4Cancer*.
- **Evan Nardone, MD**, is the facilitator for the Clinical Skills Small

Group (CSSG) for Sidney Kimmel Medical College.

Division of Hematologic Malignancies

The Division of Hematologic Malignancies experienced a year of significant transition, growth, and continued academic achievement. Following its reorganization and separation from transplant and cellular therapies, the division strengthened its distinct research identity while continuing to provide advanced, disease-focused care for patients with complex blood cancers. Through faculty recruitment, expanded clinical collaboration, national research leadership, and a strong commitment to education and mentoring, the division continues to advance its clinical and academic mission.

The Division of Hematologic Malignancies is the department's main home for academic research activities and advanced disease-focused clinical care in blood cancers. The Division provides high-acuity inpatient care at Thomas Jefferson University Hospital for aggressive and complex blood cancer patients and partners with physicians across Jefferson Health to ensure leading-edge care for these patients across the enterprise. The Division underwent a number of big changes this year, separating from our transplant and cellular therapies component as they spun off to a new division and saying goodbye to our division chief of almost 9 years as Pierluigi Porcu, MD moved on to a new opportunity. We are now a division of 11 faculty, including two PhDs. This reorganization effort

transformed the Division, culturally and operationally, building a more distinct research identity, raising its academic stature, locally and nationally, and bringing new funding from federal agencies, foundations, industry and philanthropic gifts. The Division promotes a culture of service, academic excellence, mentoring, respect, and inclusion for faculty and fellows as well as nursing and administrative staff. We continue to recruit new faculty members to address the clinical need gap in the Lymphoma and Myeloma Sections. We are planning to add two new members to the division in summer 2026.

DIVISION MILESTONES

CLINICAL SERVICE

Clinical service milestones included

- Recruitment of two junior clinical faculty
- Inclusion of the Lehigh Valley Topper Cancer Institute in the Heme Malignancies Tumor Board
- Faculty from all Regional Research Sites were included in the multidisciplinary disease group and individual disease-focused working groups.
- Growth of the international Hereditary Heme Malignancy Tumor Board led by **Gina Keiffer, MD**.

RESEARCH & ACADEMIC


Research and academic milestones reflected the division's continued growth and visibility.

- **Margaret Kasner, MD, MSCE** was chosen to serve as the Associate

FACULTY

Margaret Kasner, MD, MSCE

*Professor
Director, Division of
Hematologic Malignancies*



Seyfettin Onder Alpdogan, MD

Associate Professor

Adam Binder, MD

Associate Professor

Christine Eischen, PhD

*Herbert A. Rosenthal, MD'56
Professor of Cancer Research
Professor, Department of
Biochemistry & Molecular
Biology*

*Co-Director, Blood Cancer
Center of Excellence, Sidney
Kimmel Comprehensive
Cancer Center*

*Special Advisor to the
President, Thomas Jefferson
University Hospitals*

Chetan Jeurkar, DO

Assistant Professor

Gina Keiffer, MD

Assistant Professor

Ubaldo Martinez-Outschoorn, MD, PhD

Professor

Anjali Mishra, PhD

Associate Professor

Beatrice Razzo, MD

Assistant Professor

Lindsay Wilde, MD

Associate Professor

Michael Wysota, MD

Assistant Professor

Director for Clinical Research at Sidney Kimmel Comprehensive Cancer Center



Margaret Kasner, MD

- **Margaret Kasner, MD, MSCE**, was named Chair of the Association of American Cancer Institutes Clinical Research Innovation Committee
- **Margaret Kasner, MD, MSCE**, was appointed Chair of the American Society of Hematology (ASH) Continuing Medical Education accreditation committee
- **Gina Keiffer, MD**, co-lead the American Society of Hematology Scientific Symposium on Hereditary Hematologic Malignancies
- **Gina Keiffer, MD**, was appointed Multidisciplinary Disease Group chair
- **Gina Keiffer, MD**, was appointed as the Protocol Review and Monitoring Committee Vice-Chair
- **Gina Keiffer, MD**, achieved certification in Hereditary Cancer Risk Assessment from City of Hope
- **Ubaldo Martinez-Outschoorn, MD, PhD**, served as program lead for the TaCO research program at SKCCC
- **Ubaldo Martinez-Outschoorn, MD, PhD**, was named Senior Editor of *Cancer Biome and Targeted Therapy*
- **Chetan Jeurkar, DO**, received industry funding for an investigator initiated trial
- **Adam Binder, MD**, was awarded the Blood Cancer Center of Excellence grant, along with **Tara Rakiewicz, MD, (F'26)**.
- **Adam Binder, MD**, was selected as a Coach for the American Society of Hematology quality improvement training initiative
- Multiple publications and career development awards were submitted
- Many division faculty were invited to give talks at conferences at the national and international level

EDUCATION AND MENTORING

Education and mentoring remained central to the division's work.

- **Lindsay Wilde, MD**, assumed leadership of the Fellowship Program and was appointed the new Associate Director. She welcomed her first fellowship class in 2025.
- **Michael Wysota, MD**, spoke at the Hematologic Malignancies Lecture Series Plan
- **Tara Rakiewicz, MD, (F'26)** gave an oral presentation at ASH.
- **Tara Rakiewicz, MD, (F'26)**, and **Sean Reilly, MD, (F'26)** received Sidney Kimmel Comprehensive Cancer Center pilot project funding through Blood Cancer Center of Excellence grants for hematologic malignancy projects they are working on.
- **Katlin Fendler, CRNP**, an advanced practice clinician, gave an oral presentation at the American Society of Hematology for a project in hematologic malignancies.
- Over 600 applicants were received in this fellowship interview season with a high number of Thomas Jefferson University house staff applying for the Fellowship Program.

ADVANCED PRACTICE CLINICIANS

Mercy K. George, CRNP
Carol Gung, CRNP
Kaitlin Rancani, CRNP
Kathryn Yingling, CRNP

Division Highlight



Strong SKCCC Presence at ASH 2025 with 50 Abstracts and 9 Oral Presentations

Researchers from the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health participated in the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, held Dec. 6–9, 2025, in Orlando, Florida. The meeting program featured 50 accepted abstracts from Jefferson researchers, including nine oral presentations, highlighting the breadth of research activity in blood cancers and other hematologic disorders.

Faculty members from the Division of Hematologic Malignancies contributed extensively to this body of work. **Dr. Margaret Kasner** and **Dr. Gina Keiffer** each contributed three abstracts, **Dr. Lindsay Wilde** and **Dr. Chet Jeurkar** each contributed two abstracts, and **Dr. Adam Binder** contributed four abstracts. Additional contributions included one abstract each from **Drs. Ubaldo Martinez, Seyfettin Onder Alpdogan, Beatrice Razzo, Michael Wysota, Usama Gergis, and Xia Bi.** **Dr. Pierluigi Porcu** contributed four abstracts.

Advanced practice clinicians were also represented, with **Katlin (Katie) Fendler, CRNP**, delivering an oral presentation. These presentations and abstracts reflect the continued academic activity and research engagement of faculty and clinical staff across the division.

In addition to presentations and posters, attendees connected with colleagues at the first joint **Cardeza/Heme Malignancy Reception**. The meeting also included a shared celebration of the Mentor Award for **Sophie Lanzkron, MD, MHS**, recognizing her contributions to mentorship within the field.



CENTER CITY PHILADELPHIA

Division of Transplant & Cellular Therapy

The Transplant & Cellular Therapy Division advanced significantly in 2025, reflecting progress in clinical volume, program coordination, and therapeutic innovation. Through multidisciplinary relationships, expanding clinical trial activity, and collaboration across Jefferson and Lehigh Valley Health Networks, the Division continues to strengthen its role in delivering highly specialized transplant and cellular therapy services.

The Transplant and Cellular Therapy Division (TCT) is led by Director **Usama Gergis, MD, MBA**, with support from Administrative Director **Mike Dugan, MBA**. On August 17, 2025, **Joseph Van Galen, MD, MS**, joined the Transplant & Cellular



Joseph Van Galen, MD, MS

Therapy Division as a BMT attending, further enhancing the Division's transplant

and cellular therapy programs. 2025 was a time of transformative growth for the Transplant and Cellular Therapy Division, increasing total procedures by 68% and nearly doubling the number of CART therapy infusions over the prior year.

The Division maintains strong relationships with the Hematological Malignancy Division as well as with other Thomas Jefferson University Hospital programs to provide non-hematologic disease therapies.

Additionally, the Transplant and Cellular Therapy team is accruing for a number of clinical trials, including a groundbreaking trial for

an allogeneic transplant therapy.

Dr. Gergis continues to serve as the Enterprise Medical Director of both the Thomas Jefferson University Hospital Center City Campus and the Lehigh Valley Health Network Topper Cancer Institute Transplant and Cellular Therapy Program. Both campuses have exchanged Standard Operating Procedures and coordinated workflows, supported by shared clinical resources. This collaboration has fostered mutual growth and advancement across both programs. See figure 18 on the next page.

FACULTY

Usama Gergis, MD, MBA

Professor

Director, Division of Transplant & Cellular Therapies

Enterprise Medical Director, Thomas Jefferson University Hospital

Enterprise Medical Director, Lehigh Valley Health Network, Topper Cancer Institute, Transplant and Cellular Therapy Program



Xia Bi, MD

Assistant Professor

Joanne Filicko-O'Hara, MD

Professor

Joseph Van Galen, MD

Assistant Professor


ADVANCED PRACTICE CLINICIANS

Rachael Cloud, CRNP

Lisa J. Kearns, CRNP

Abby Lerner, CRNP

Figure 18: Transplant and Cellular Therapy Volumes 2021–2025



Division of Population Science

The Division of Population Science enters 2026 with strengthened direction, expanded collaboration, and growing momentum across research, funding, and strategic planning. Under Dr. Hoda Badr's leadership, the Division is advancing population science across the cancer control continuum while building the infrastructure needed to improve care delivery, reduce disparities, and better support patients, families, and communities across Jefferson's catchment area.

The Division of Population Science advances interdisciplinary cancer population research within the Department of Medical Oncology and the Sidney Kimmel Comprehensive Cancer Center. Our work spans the entire cancer control continuum—prevention, early detection, treatment quality, survivorship, and caregiver support. It examines how individual, social, environmental, and system-level factors shape cancer outcomes across Jefferson's diverse catchment area.

Using behavioral, epidemiologic, and data-driven methods, we develop and evaluate tailored interventions in both healthcare and community settings, with a sustained emphasis on reducing disparities, strengthening person- and family-centered cancer care, and translating evidence into real-world practice. These efforts

reflect our commitment to generating rigorous, contextually grounded evidence that improves cancer care delivery and population health, and creates meaningful, measurable benefits for the patients, families, and communities we serve.

LEADERSHIP & STRATEGIC DIRECTION

Since assuming the role of Division Director in July 2025, **Hoda Badr, PhD**, has taken deliberate steps to reorient the Division toward a more cohesive, strategic, and enterprise-aligned direction. The Division now benefits from multiple touchpoints for collaboration, including regular scientific exchange and team-building activities that strengthen faculty connectivity. The Division also held its first strategic planning retreat, which clarified its mission, articulated a unifying vision, and established a shared

framework to guide how the Division organizes and communicates its work.

The framework emphasizes three key areas:

- grounding research in the lived experiences of patients, caregivers, and communities
- leveraging multiple data streams to develop an integrated understanding of risk, care, and outcomes
- designing interventions that are contextually tailored, scalable, and responsive to health system and community needs

Building on this framework, faculty identified two high-priority, actionable needs for advancing divisional research:

- 1) enhancing competitiveness for external grants and diversifying funding streams, and

FACULTY

Hoda Badr, PhD

*J. Ewing Mears Endowed Professor
Director, Division of Population Science
Associate Director, Sidney Kimmel Comprehensive Cancer Center Population Science*



Nikita Nikita, PhD, MPH

Instructor, Research Excellence

Hee-Soon Juon, PhD

Professor, Cancer Biology

Amy Leader, PhD, MPH

Professor

Grace Lu-Yao, PhD, MPH

Professor

Ronald Myers, PhD

Professor

Munjireen Sifat, PhD, MPH

Associate Professor

Chun Wang, MD, PhD

Assistant Professor

Kuang-Yi Wen, PhD

Professor

Hushan Yang, PhD

Professor

2) developing coordinated data extraction, collection, and management processes to support division-wide research needs.

2026 STRATEGIC PRIORITIES, & ROAD MAP

These priorities provide a clear road map for 2026. Early efforts will focus on enhancing the Division's competitiveness for external grants by assembling interdisciplinary working groups to develop large multi-PI applications and by diversifying funding streams through targeted engagement with foundation, corporate, and philanthropic partners. These expanded funding pathways will allow us to accelerate promising ideas, pilot innovative care models, and deliver interventions that reach patients and families more quickly.

In parallel, the Division will initiate structured conversations with enterprise data teams to establish coordinated processes for data extraction, collection, and management that support research across the Division, the Department, SKCCC, and the College of Population Health. To

strengthen methodological and scientific capacity, we will prioritize strategic hires in implementation science, geospatial analytics, clinical epidemiology, health economics, and core mission areas such as survivorship.

As part of our enterprise-facing strategy, the Division will also begin expanding its research footprint beyond Center City, developing collaborations and infrastructure to support population science research across Jefferson's regional sites. Investment in these areas will:

- expand the Division's ability to generate transformative science,
- integrate population science across clinical operations, and
- translate discoveries into better prevention, earlier detection, and more equitable outcomes.

Together, these efforts position the Division to serve as a connector across SKCCC, SKMC, Jefferson Health, the College of Population Health, and community partners. They support more integrated grants, improving data infrastructure, and advancing institutional priorities, including future

cancer center support grant renewal.

RESEARCH HIGHLIGHTS

In 2025, Division faculty produced several high-impact publications across clinical outcomes, cancer screening, community engaged research, and supportive care.

Work led by **Grace Lu-Yao, PhD, MPH, Nikita Nikita, PhD, MPH, Hushan Yang, PhD**, and colleagues contributed important real-world evidence for treatment decision-making in advanced prostate cancer. A population-based study in the *Journal of Geriatric Oncology* showed low and comparable septicemia rates for abiraterone and enzalutamide among older adults, while a study in *JNCI Cancer Spectrum* found that diabetes significantly increases the risk of unplanned hospitalization, underscoring the need for coordinated oncology–primary care management.

In the area of cancer screening and communication, **Ronald Myers, PhD**, co-authored a national consensus report in *Cancer* outlining challenges and future directions for shared decision-making in lung

cancer screening. Faculty advancing community engaged and digital approaches including **Amy Leader, PhD, MPH, Kuang-Yi Wen, PhD, Munjireen Sifat, PhD, MPH**, and **Hee-Soon Juon, PhD**, published studies in *Translational Behavioral Medicine*, *Preventive Medicine Reports*, *JMIR Cancer*, and the *Journal of Racial and Ethnic Health Disparities*. These papers demonstrated the feasibility of CHW-driven smoking cessation and lung cancer screening interventions among Asian immigrants, identified correlates of e-cigarette use in national survey data, engaged men in prostate cancer genetics education, and documented cancer-related beliefs in Chinese-speaking adults in our catchment.

Finally, work led by **Dr. Badr** strengthened the Division's contributions to survivorship and supportive care. A longitudinal study in *JAMA Otolaryngology–Head & Neck Surgery* demonstrated that caregiving for head and neck cancer patients leads to substantial employment disruption and mental health burden—highlighting the need for early identification of at-risk

caregivers and proactive supports to prevent long-term socioeconomic and psychological consequences.

Complementing this work, a study in *BMJ Supportive & Palliative Care* showed that unmet psychological and health system/information needs are key drivers of distress among advanced cancer patients, underscoring the importance of timely screening and service delivery models that connect patients with tailored supportive resources.

Together, these publications illustrate a coherent, impactful research program spanning clinical effectiveness, screening and early detection, community and behavioral science, and supportive care—advancing the Division’s strategic priorities and strengthening its visibility locally and nationally.

FUNDING

In 2025, faculty in the Division secured several new awards that reinforce its emerging scientific framework. **Dr. Leader** received a CDC Prevention Research Center award (U48DP006801) to evaluate a shared decision-making tool that supports

value-aligned treatment decisions. This emphasis on patient-centered communication and real-world implementation is echoed in the enterprise-wide PCORI initiative led by **Drs. Chapman and Wen**, *Optimizing Treatment Outcomes in Cancer Patients with Metastatic, Stage II and III Cancer*, which embeds electronic patient-reported outcomes into routine care.

Several additional 2025 awards expand the Division’s capacity for data-driven, multilevel research. **Dr. Lu-Yao** received a P30 administrative supplement focused on epigenetic aging and immunotherapy, as well as a SKCCC Goal Line Award for *Using Artificial Intelligence and Big Data to Optimize Personalized Treatment for Advanced Prostate Cancer*.

Complementing these efforts, **Dr. Nikita** received a CRIC Pilot Award supporting a smoking-cessation intervention for patients initiating immunotherapy. **Dr. Badr’s** NCI-funded R01 administrative supplement, *Long-Term Cancer Survivorship Care for Older Adults*, expands the Division’s survivorship research by examining multilevel determinants of

outcomes among long-term survivors.

Implementation-focused improvements in care delivery are further reflected in **Dr. Leader’s** award from the Academy of Oncology Nurse and Patient Navigators, *Automating PIN Reimbursement at a Large Academic Health Care System*.

Taken together, these awards illustrate a coherent and growing portfolio focused on patient-centered communication, multilevel data integration, precision analytics, and real-world implementation. They advance the strategic priorities identified during the 2025 retreat and strengthen the Division’s competitiveness for future interdisciplinary, multi-PI, and diversified funding opportunities

CONCLUSION

The Division is entering 2026 with a clear scientific direction, strengthened collaborative infrastructure, and growing momentum across grants, publications, and strategic partnerships.

By expanding our data capabilities, diversifying funding streams, and extending our research footprint across Jefferson’s hubs, we are positioning

Population Science to play an increasingly central role in institutional initiatives—from improving care delivery to advancing equity across the catchment.

Our work directly supports Sidney Kimmel Comprehensive Cancer Center’s mission and contributes foundationally to future CCSG renewal efforts. With continued investment and cross-enterprise collaboration, the Division is poised to deliver the rigorous, actionable evidence needed to improve outcomes for patients, families, and communities across Jefferson Health.

Division Highlights

Hoda J. Badr, PhD, Appointed Director of Population Science



The Department of Medical Oncology and the SKCCC welcomed **Hoda J. Badr**,

PhD, as the Director of the Division of Population Science in the Department of Medical Oncology, as of July 1, 2025.

Dr. Badr joined Jefferson from the Baylor College of Medicine Dan L. Duncan Comprehensive Cancer Center, where she served

as Leader of the Cancer Prevention and Population Sciences Program and Deputy Section Chief of Epidemiology and Population Sciences.

Her research centers on improving the well-being of cancer patients and their families through evidence-

based psychosocial and behavioral interventions. She is recognized nationally and internationally for her work to refine the methods and models used to understand how patients and caregivers navigate and cope with the cancer experience.

Division of Population Science Showcased 10 Posters at ASPO 2025

Congratulations to the Division of Population Science on 10 posters presented at the American Society of Preventive Oncology Conference, held April 6-8, 2025, in Philadelphia.

This strong showing reflects the division's continued commitment to advancing research in cancer prevention, population science, and health outcomes. The conference provided an important opportunity to share new findings, highlight ongoing work, and represent Jefferson on a national stage.

Among the presenters, **Dr. Kuang-Yi Wen** presented her poster on lung cancer screening among Asian Americans. **Dr. Hee-Soon Juon** presented her poster on the quality of life among Asian American

patients with chronic hepatitis B virus. These presentations helped bring attention to important issues affecting Asian American communities and underscored the division's focus on research that addresses real needs in patient care, prevention, and quality of life.

Dr. Munjireen Sifat presented two posters at the conference. Her work included *Nativity Differences in Awareness and Knowledge About HPV Infection and Vaccination Among Foreign- and US-Born Asians: Findings from a National Population-Based Sample*, as well as *a Comparative Analysis of Mammography Data Across a Mobile Cancer*



Screening Unit and its Health System Static Site Counterparts.

Together, these projects reflect the breadth of research taking place within the Division of Population Science and its emphasis on screening, education, access, and population-based analysis.

The division's participation in ASPO was a meaningful accomplishment and a clear reflection of the

talent, dedication, and productivity of its faculty, researchers, and trainees.

Having 10 posters represented at a national conference is an impressive achievement and speaks to the depth of work being done across the division.

Congratulations to Population Science, and thank you all for your hard work.

The Population Science Division Supports South Philadelphia Through Food Drive

On November 6, 2025, the Division of Population Science came together for a food drive effort that supported community pantries in South Philadelphia. Through this initiative, PopSci was able to pack two community pantries, helping provide needed nonperishable items to local residents. The effort reflects the division's commitment not only to research and education, but also to showing up for the community in meaningful and practical ways.

The food drive was a reminder that small acts of generosity can have a

real impact. By collecting and organizing donations, members of the division contributed to a shared effort to support neighbors facing food insecurity. Packing two community pantries was an important accomplishment, and it demonstrated what can happen when a group comes together around a common purpose.

The drive also remained ongoing after the initial drop-off. Additional nonperishable items were collected through Wednesday, November 19, with plans for another drop-off before the Thanksgiving holiday.

Donations could be brought to Suite 314 Ben Franklin and placed on the table right inside the suite door, making it easy for faculty and staff to continue participating in the effort.

This food drive was a meaningful example of community engagement in action. By supporting local pantries in South Philadelphia, the Division of Population Science extended its impact beyond the



workplace and into the broader community. The success of the drive speaks to the generosity of those who contributed and to the division's ongoing spirit of service.

The Division of Population Science 2025 Retreat

The Division of Population Science retreat brought colleagues together for a meaningful day of planning, reflection, and connection. Designed as both a working session and a time to step back together, the retreat created space for the division to focus on where it was headed and how it could continue to grow.

The day opened with a welcome activity that asked participants to imagine it was one year in the future and that a national newspaper was featuring the Division of Population Science. Team members

were invited to think about the headline they hoped to see, write it on a Post-it note, and place it on the board at the front of the room. That prompt set an energizing tone for the day and encouraged everyone to think big about the division's future.

The retreat also had a warm and welcoming atmosphere that made the day feel both productive and collegial, adding to the overall



sense of gathering and community as colleagues could settle in, share breakfast, and enjoy time together beyond the usual




pace of daily work. The retreat was not only about strategy, but also about strengthening relationships across the division.

Throughout the day, participants engaged in active discussion and group exercises that focused on the division's strengths, challenges, and opportunities. Notes captured on the boards reflected thoughtful conversation about collaboration, stronger touch points, shared space, structured integration with clinical partners, and better communication across faculty. Additional ideas included building collaborative MPI grant opportunities within and across divisions, creating structures that support interaction across the enterprise, and identifying projects tied to prevention science, implementation science, and translational research.

Team members also highlighted the importance of making the division's strong methods more visible and better understood across the broader faculty community.

The retreat further underscored the division's interest in turning ideas into action. Practical themes that emerged included the potential creation of a task force, a coordinated process to prioritize data management, and shared resources related to data extraction and REDCap support. Colleagues contributed ideas and fully participated in the discussion, reflecting a team that was engaged in shaping its future together.

The Division of Population Science retreat was a thoughtful and successful gathering that balanced strategic planning with connection, celebration, and a shared sense of purpose.



Division of Supportive Oncology

As an essential component of care at the Sidney Kimmel Comprehensive Cancer Center, Supportive Oncology services focus on the physical, social, and emotional needs of cancer patients. Clinicians and professionals collaborate to meet the holistic needs of patients throughout the entire span of their diagnosis, treatment, and survivorship. As the Center continues to expand its geographic reach, Supportive Oncology services also continue to impact more patients. In FY25, most of SKCCC's approximately 21,000 annual patients were served by one or more of Supportive Oncology's core functions. The total volume of patients supported in FY25 through their cancer treatment and beyond surpasses years prior, but so too does the depth of services offered by each team within the Division.

FISCAL YEAR 2025 IN REVIEW

Compared to FY24, Supportive Oncology saw an increase in:

- the number of patients served by Supportive Oncology
- the average number of interactions per patient
- the number of patients, families, and caregivers connected with community partners
- the access, availability, and utilization of palliative care providers across the Jefferson Health enterprise
- the number of attendees at the Cancer Support and Welcome Center
- the amount of programs offered within the

Cancer Support and Welcome Center, and

- the academic contributions of SKCCC's interdisciplinary researchers and clinicians to the development of best practices in patient-centered cancer care

Dr. Brooke Worster was promoted to Professor on June 9, 2025.



Brooke Worster, MD

On September 1, 2025, we welcomed **Angela Kuehn, DO**. Dr. Kuehn specializes

in internal medicine, with a strong focus on supportive



Angela Kuehn, DO

oncology for patients with complex, chronic, and life-limiting illnesses.

UTILIZATION AND IMPACT

In FY25, Supportive Oncology services at the SKCCC played a vital role in the care of approximately 21,000 unique patients across the Jefferson Health enterprise. A significant portion of these patients were supported

FACULTY

Brooke Worster, MD

*Professor
Enterprise Director, Supportive Oncology
Medical Director, MS in Medical Cannabis and Business,
Jefferson Institute of Emerging Health Professions*



Max Geisinger, MD

Angela Kuehn, DO

Assistant Professor, Supportive Oncology

Thomas Patrick Lynch, MD

Ihuoma Njoku, MD

Medical Director, Psychiatric Oncology

Assistant Professor, Medical Oncology

Elham Siddiqui, MD

*Assistant Professor,
Palliative Care*

ADVANCED PRACTICE CLINICIANS

Alyssa Christofas, CRNP

Daniel Deguisto, CRNP

Molly Hanson, CRNP

Emma Harnitchk, CRNP

Lauren McGrath, CRNP

through one or more core services, reflecting both the breadth and depth of the division's impact. Care navigation reached 12,785 unique patients, while 3,352 unique patients completed a supportive oncology appointment.

Nutrition services supported 2,186 unique patients, and the Cancer Support and Welcome Center welcomed 3,428 patients and caregivers who attended a support or education program.

Supportive Oncology also continued to make a meaningful difference in addressing patients' holistic needs. Nearly 90% of patients on active cancer treatment completed a health-related social needs assessment, helping to identify and respond to challenges beyond medical care. More than 1,000 patients and families were connected with community resources, and \$1.2 million in external financial assistance payments were secured to support patient accounts. Since program inception in 2023, the Home Care program also recorded 454 total visits, further demonstrating the expanding reach of Supportive Oncology services.

Together, these efforts highlight the division's commitment to comprehensive, patient-centered care that

supports individuals and families throughout the full cancer journey. From navigation and nutrition to psychosocial support, financial advocacy, home care, community resources, and education programs, Supportive Oncology continued to provide essential services that helped patients access care, address practical needs, and receive support beyond their medical treatment.

SOCIAL WORK

In FY25, Social Work services continued to play a critical role in supporting patients and their families by addressing essential needs that impact care and well-being. A total of 1,233 smoking cessation counseling visits were completed, benefiting 78 unique patients and generating \$93,000 in billable charges.

Transportation services supported 373 unique patients, with an average of 20 rides per patient with more than 5,000 additional rides provided compared to FY24.

In addition, 321 patients benefited from food pantry services, and 1,085 patients and caregivers were supported through community organizations and programs.

These services were further strengthened through targeted programs and

partnerships that helped reduce financial and logistical barriers to care.

Social Work facilitated \$281,700 in support through community partnerships, assisting 296 patients and families in addressing financial toxicity. Through Jefferson's Free Breast and Cervical Cancer Screening Program, 300 medically underserved women were screened, resulting in seven breast cancer diagnoses. Additional support included local lodging for 35 patients, totaling \$62,716, and fertility preservation services for 14 patients, an increase from FY24.

Transportation services were supported by the American Cancer Society, \$50,000; American Lung Association, \$7,500; Colamecco Transportation Fund, \$50,000; Ken Knight Fund, \$50,000; and Johnson & Johnson, \$50,000.

Together, these efforts highlight the comprehensive and coordinated approach of Social Work services in FY25, ensuring that patients received practical, financial, and supportive resources throughout their cancer journey.

PSYCHOSOCIAL NEEDS ASSESSMENT

The Psychosocial Needs Assessment helped identify and respond to health-related social needs among patients receiving cancer

care. A total of 12,101 unique patients were screened, an increase of more than 2,000 patients compared to FY24. Among those screened, 1,296 patients indicated a need for assistance with at least one health-related social need, representing 11% of patients screened. In addition, 37% of assessments were completed by patients through MyChart, reflecting continued use of digital tools to support screening and access.

ONCOLOGY NUTRITION

Oncology Nutrition services continued to expand their reach and impact across the enterprise, supporting 2,186 unique patients in FY25. A total of 11,519 encounters were completed, averaging five encounters per patient, and representing more than 1,000 additional encounters compared to FY24. These services were supported by 6.5 full-time equivalents, reflecting a strong and growing team dedicated to meeting the nutritional needs of patients throughout their cancer care.

Malnutrition screening was completed at all locations to identify patients at risk before, during, and after treatment, ensuring early intervention and ongoing support. In addition to clinical services, the onsite food pantry provided 321 bags of food to patients in need, helping address food insecurity

as part of comprehensive care. The department also extended its reach beyond individual encounters by participating in cancer screening days, survivorship days, and multiple classes offered through the Cancer Support and Welcome Center.

Education and outreach remained a key focus, with team members providing talks for patients and professionals through organizations such as the Leukemia and Lymphoma Society, the Pancreatic Cancer Symposium, and Pancreatic Cancer Survivor Day. The team also participated in the Enfit Transition to support enteral fed patients and precepted interns through the Jefferson Dietetic Internship Program. Together, these efforts highlight a comprehensive approach to oncology nutrition that integrates clinical care, education, and community support.

CANCER SUPPORT & WELCOME CENTER

The Cancer Support and Welcome Center continued to serve patients, caregivers, staff, and community members through a growing schedule of programs and services. A total of 411 programs were offered, representing more than 70 additional events compared to FY24. These programs reached 3,428 participants

and supported 4,537 in-person, walk-in visits to the Center, an increase of more than 500 visits compared to FY24.

Programs were offered in several formats to meet different needs across the Jefferson enterprise. Of the programs offered during FY25, 22% were in-person only, 48% were virtual only, and 23% were offered as a hybrid of virtual and in-person participation. The top program categories included:

- Support and Networking at 38%,
- Mind-Body programs at 25%, and
- Education-focused programs at 12%.

The Legal Clinic also expanded its support, assisting 65 total patients in FY25 compared to 39 patients in FY24.

Together, these efforts reflect the Cancer Support and Welcome Center's continued role in connecting patients, caregivers, and the community with education, support, and practical resources.

FINANCIAL ADVOCACY

Financial Advocacy supported patients through 20,105 total patient interactions in 2025, representing a 1.5% increase compared to the prior fiscal year.

GRANTS & AWARDS

CELESTE VAUGHN-BRIGGS

2025 Co-Chair, Program Planning Committee. *American Psychosocial Oncology Conference*

GREGORY GARBER

2024 Founders Award Honoree. *Living Beyond Breast Cancer*

LORA RHODES

Supporting Lung Cancer Patients with Assistance/Quality of Life. *William Lake Foundation, \$10K Grant*

Supporting Rides for Lung Cancer Patients.

American Lung Association, \$10K Grant

REBECCA CAMMY

Quantification of Non-Billable, Psychosocial Interventions to Develop a Sustainable Model for Supportive Oncology Care Delivery. *Cambia Health Foundation Sojourns Scholar*

SDOH Data Collection and Workflow to Contribute to Best Practices Nationally in Ambulatory Oncology Setting. *American Cancer Society, \$75K Grant*

From Screening to Support: A Multi-Method Analysis HRSN Integration in Cancer Care. *Thomas Jefferson University Clinical Research Institute Provost's Pilot Award, \$20K Grant*

BROOKE WORSTER

Assessing Benefits and Harms of Cannabis Use in Patients Treated with Immunotherapy for Cancer: A Prospective Cohort Study. *National Cancer Institute*

Cannabis Use and Outcomes in Ambulatory Patients with Cancer: A 12-Month Cohort Study. *National Cancer Institute*

Medical Marijuana's Effect on Opioid Use for Individuals with Chronic, Intractable Pain and Opioid Use Disorder. *PA ACRC/CR Medical Marijuana Collaboration*

Medical Marijuana, Cannabis, and Cannabinoids for Patients with Significant Symptom Burden in Serious Medical Conditions. *PA ACRC/CR Medical Marijuana Collaboration*

The team processed 893 Compassionate Care applications, a 29% increase from FY24, and secured \$1.2 million in external financial assistance payments to patient accounts, representing 25% more funding than FY24.

Through the Free Drug Program, Financial Advocacy also helped save \$12 million in hospital charges and achieved \$2.2 million in pharmacy acquisition savings.

ONCOLOGY NAVIGATION

Oncology Navigation continued to play a key role in supporting patients throughout their cancer care journey. 12,785 unique patients benefited from navigation services, with a total of 37,561 distinct navigation outreaches performed. In addition, 96.4% of patients discharged from the hospital completed post-discharge follow-up, reflecting strong continuity of care and patient engagement.

Program advancements further strengthened the impact of Oncology Navigation. Transition of Care Navigation led to a 65% reduction in readmissions for Center City and was expanded to include patients diagnosed with hematologic malignancies.

Navigation services were also extended through collaboration with surgical

oncology to support patients age 65 and older. Additional initiatives included:

- the launch of a collaboration with Inspirata for pathology reports
- the transition of three multidisciplinary clinics to Honickman, and
- a Principal Illness Navigation (PIN) billing pilot that generated \$53,450 in total payments.

The team also successfully submitted an application for the AONN Tools to Advance Navigation grant for \$250,000.

ONCOLOGY NAVIGATION STAFF ACHIEVEMENTS

The Oncology Navigation team received significant recognition for their contributions and excellence in patient care.

- The AONN 2024 Exceptional Research in Navigation Award was presented to **Silpi Sinha Ray, MA, MBA; Atrayee Basu Mallick, MD; Jackie Miller, MSN, RN, OCN; and Valerie Csik, MPH, CPPS**, for their work on enhancing sarcoma care through patient navigation in a multidisciplinary clinic.
- Daisy Award nominations were received by **Sue LaSalle,**

MSN, RN, OCN; Chris Murray, MSN, RN, OCN, CBCN; and Patti Day, MSN, RN.

- **Ashley Spencer, BSN, RN**, was recognized with the Jefferson We Rise by Lifting Others Award.
- **Rick Klass, BSN, RN, CPAN**, was nominated for the Schwartz Center 2025 National Compassionate Caregivers of the Year Award.
- Additional recognition included Mission Moments for **Noreen Wielgus, MSN, RN**, and **Beverly Hale, BSN, RN-BC**, and
- The BEE Award was presented to **Kim Primavera, MA.**

PARTNERSHIPS AND ENGAGEMENT

COMMUNITY PARTNERSHIPS

Community partnerships provided \$566,165 in support, donated goods, and services to patients and their families in 2025. This included:

- American Cancer Society lodging support for 26 patients, totaling \$54,184.
- Bringing Hope Home support for 65 families, with \$86,217.59 in financial assistance provided.

- Breathing Room Foundation supported 552 families with \$77,260 for food, \$4,865 for utilities, \$21,750 for housing, and \$850 for transportation. Breathing Room Foundation also provided \$40,305 in donated goods, along with an additional \$135,000 to support Children's Programs for Jefferson families.
- Legacy of Hope supported 96 families with \$50,007 for housing, \$15,186 for utilities, \$10,732 for food, \$9,472 for transportation, and \$1,000 for other expenses.
- Family Reach supported 325 patients, including 147 children, with assistance for housing, food, medical needs, and transportation. This included \$10,421 for housing, \$27,082 for food, \$6,508 for medical needs, and \$6,508 for transportation.

GIFT FUNDS

In FY25, Gift Funds provided \$281,700 in total support to 296 patients. This included:

- \$6,100 from Cancer Legacy in Action, which supported 16 brain tumor patients
- \$10,900 from David's Dream and Believe,

which supported 38 head and neck cancer patients

- \$15,600 from the Jack and Ann Neary Kindness Fund, which supported 26 colon cancer patients
- \$1,600 from Links for Lungs supported seven lung cancer patients
- Additional support included \$18,400 from the newly established Live Like Brent Foundation, which supported 48 patients
- \$18,000 from the Sean Strong Family Grant, which supported 41 patients and families with child and family needs
- The Paige Tibbetts Young Adult Fund provided \$167,200 and supported 85 patients ages 18 and 40
- The Christine Fox Fraunheim Fund provided \$6,800 and supported seven uveal melanoma patients with travel and household support
- The newly established Luker Fund provided \$32,200 and supported 16 uveal melanoma patients with travel and lodging
- Ride Hard Breathe Easy provided \$4,900 and supported 12 patients.

Breast Cancer Program support also continued through several partners and funds.

- PA-BCCEDP provided a \$35,000 annual contract with reimbursed services for FY25
- The American Breast Cancer Foundation provided \$11,000 for the Breast and Cervical Cancer Screening Program
- EPIC provided \$50,000 for the Breast Cancer Quality of Life and Breast and Cervical Cancer Screening Program
- Helen's Angels provided \$25,000 for Breast Cancer Quality of Life support
- Pink Clover/Bastazo provided \$5,000 in quality-of-life funds for breast and other cancer types

Gift bag donations further supported patients receiving care.

- The Pink Clover Foundation donated 250 snack bags for infusion patients
- Jefferson Health Plans provided staff retreat donation gift and snack bags for patients in infusion
- The Bold Boobs Collective donated 100 gift bags from the newly formed nonprofit

- Bright Hope Baptist Church donated 100 gift bags of various items
- A Sister's Heart donated 15 gift baskets in memory of a former Jefferson Breast Cancer patient

IBX HOME CARE PILOT*

The IBX Home Care Pilot engaged 454 unique patients from the start of the pilot in August 2023 through June 2025. During that time, 111 total visits were completed, with an average of approximately four visits per patient. The program also supported the creation of 101 advance care plans, with 92% of patients completing an advance care plan. IBX patients averaged three times more visits with Supportive Oncology compared to patients not in the program, and the pilot saw two times more visits per patient than FY24.

PATIENT GRATITUDE

Patient Gratitude reflects the impact of Supportive Oncology services through the voices of those receiving care. These experiences highlight the compassion, advocacy, and support provided by team members, illustrating how clinical expertise and human connection come together to support patients and their families

throughout their cancer journey.

“Celeste Vaughn-Briggs, LCSW, please know you are both very much appreciated! Last week in the clinic with Dr. Adekeye, the [patients'] family spoke so very highly of you, it brought me to tears! Often, we hear only of the bad patient experiences, this was an unprovoked account of ALL you have done for [patient], her husband was so grateful. Thank you for always taking such great care of our patients!”

“Rosemarie (Rosie) Giannopoulos, MSW, LSW, provides such a positive experience for our patients. I hear Rosie on the phone with patients all the time being encouraging, understanding, kind, persistent and no-nonsense when they need it. She helps the patients to express their emotions and to grieve and come to terms with their diagnosis and they always feel supported by her. I often hear her walking in while on her cell phone in the morning with a patient because when they call in need, she answers the call, she always supports them. Rosie has a way of understanding what the patient needs, whether it be tough love, no-nonsense or gentle guidance and offers it with patience and understanding. She has a gift

*Data measured from pilot start, August 2023 through June 2025

and doesn't even realize it; There is no specific event, it is her constant commitment to our patients and their families that shines through every day. She has been an amazing team member and we all value her."

"I am nominating Rosemarie (Rosie) Giannopoulos,

MSW, LSW, for all of the outstanding care she provides to our patients on a daily basis. I have witnessed Rosie step up to the plate when our patients needed it the most. She displays an exceptional level of compassion and expertise. She advocates for the patients who do

not have the ability to do so for themselves. Rosie has navigated some of the most difficult situations with grace. She has found shelter for our unhoused patients. She has coordinated inpatient/outpatient substance abuse treatment for a patient with stage IV cancer. No matter

how difficult the situation is Rosie delivers unbiased care. Our patients are truly lucky to have her on their team. Please consider Rosie for the Rise Award because she always rises to the occasion and deserves to be recognized."

Division Highlights

Breast Donation Event Brings Comfort and Community Support to Cancer Patients

Our Breast Donation Event on December 5, 2025, was a patient-centered community engagement effort at the Sidney Kimmel Comprehensive Cancer Center. Staff connected with patients in a welcoming environment. Team members engaged in conversation and outreach, creating an approachable

space for those receiving care. The event also included refreshments and gift bags from The Bold Boobs Collective, reflecting Supportive Oncology's focus on comfort, dignity, and meaningful touches that enhance the patient experience.



Bright Hope Baptist Church Hosts "Bags of Hope" Donation Event for Jefferson Cancer Patients

Supportive Oncology partnered with Bright Hope Baptist Church to host a **"Bags of Hope" Donation Event** at the Honickman Center on October 30, 2025. The event brought together staff and

community members to support patients through thoughtfully assembled care packages, creating a welcoming and supportive environment within the Cancer Support Center. Gift bags, including

contributions from partners such as The Bold Boobs Collective, were made available to patients, alongside refreshments and opportunities for connection. The event reflected a shared

commitment to enhancing the patient experience through community partnership, compassion, and meaningful acts of support.



Jefferson Abington Hospital and Asplundh Cancer Pavilion

Jefferson Abington Hospital and Asplundh Cancer Pavilion hematology and oncology team provides comprehensive outpatient, infusion, and inpatient consult services for a high-volume community practice. The group is increasingly integrated with Sidney Kimmel Comprehensive Cancer Center and the Department of Medical Oncology in center city through clinical trials, multidisciplinary collaboration, tumor boards, research meetings, and educational training for fellows and residents.

This group currently comprises 12 hematologist/medical oncologists and nine nurse practitioners covering the outpatient office, infusion, and inpatient service. In 2025, we welcomed **Rebecca Masel, MD**, as a new faculty hire, further strengthening



Rebecca Masel, MD

our clinical team and capacity to serve patients. The group is led by **Steven Cohen, MD**, who serves as Chief of the Division of Hematology/Oncology at Jefferson— Abington Hospital and Chief of Cancer Services at Jefferson Abington Hospital and Asplundh Cancer Pavilion.

He is also the Chief of GI Medical Oncology and a vice-chair in the department of medical oncology at TJUH. **Christian Fidler, MD**, serves as the Clinical Director of Operations. **Sheel Patel, MD** serves as Asplundh regional research site Physician Leader and oversees the NP program. **Melanie Nordlinger, MD**, oversees head and neck and melanoma oncology. **Avnish Bhatia, MD**, oversees the Same Day Next Day program. All physicians with the exception of **Dr. Cohen** (exclusively GI oncology) see a broad range of hematology/oncology patients as is typically needed in community practice. However, each physician has a specific disease-site focus, including breast, lung, gastrointestinal, malignant hematology, genitourinary, head and neck, or melanoma. Of our nine nurse practitioners, one is exclusively GI-focused (with Dr. Cohen),

six are aligned with care teams consisting of two or three physicians, one is exclusively inpatient, and one exclusively covers infusion. All physicians rotate to cover a busy inpatient consult service averaging over 30 patients at a time. They spend an average of 10 weeks doing inpatient consults. The group's outpatient practice is at Asplundh Cancer Pavilion, which is a TJUH and SKCCC facility, with their inpatient consult work located at Jefferson Abington Hospital. The clinical practice is busy, providing care for more than 100 outpatient visits per day and treating more than 75 patients per day in the infusion unit at Asplundh Cancer Pavilion. See figure 19 on page 60.

The group is increasingly integrated with SKCCC and the Center City Department of Medical Oncology. Physicians participate in Multidisciplinary Disease

PHYSICIANS

Steven Cohen, MD

Chief, Division of Hematology/Oncology, Jefferson Abington Hospital
Chief, Cancer Services, Jefferson Abington Hospital and Asplundh Cancer Pavilion
Chief, Gastrointestinal Medical Oncology, Department of Medical Oncology
Vice-Chair, Medical Oncology, Thomas Jefferson University Hospital
Professor



Avnish Bhatia, MD

Clinical Assistant Professor

Frederick Fellin, MD

Clinical Assistant Professor

Christian Fidler, MD

Clinical Director, Operations, Jefferson Abington Hospital
Clinical Assistant Professor

Kevin Hou, MD

Clinical Assistant Professor

Amy MacKenzie, MD

Clinical Associate Professor

Rebecca Masel, MD

Clinical Assistant Professor

Melanie Nordlinger, MD

Clinical Instructor

Ankur Parikh, DO

Clinical Associate Professor

Sheel Patel, MD

Clinical Assistant Professor
Physician Leader, Regional Research, Asplundh Cancer Pavilion

Group (MDG) meetings according to their disease area of interest, and many clinicians also participate in enterprise-wide tumor boards and clinical and research meetings. In collaboration with center city colleagues, appropriate clinical trials are opened at Asplundh for the patient population.

In terms of education, Abington has a dedicated fellowship position that serves as a separate track within the Jefferson Hematology/Oncology Fellowship. The program currently has three fellows, one in each year, who each spend four months rotating through the outpatient setting at Asplundh and the inpatient consult service at Jefferson Abington Hospital. Jefferson Abington Hospital's internal medicine residents also rotate with the team regularly to gain additional experience in hematology/oncology. We also have a fair number of external internal medicine residents. We provide lectures for Jefferson Abington Hospital's internal medicine residency as a whole in hematology and oncology.

2025 ACCOMPLISHMENTS

- **Dr. Steven Cohen** was appointed President of the Pennsylvania Society of Oncology and Hematology

(PSOH), an affiliate of the American Society



Steven Cohen, MD

of Clinical Oncology, for a two-year term.

- **Dr. Christian Fidler** presented four lectures at the American College of Physicians Philadelphia Board Review Course for Internists.
- **Dr. Fidler** presented an abstract for the American Society of Hematology entitled *Imatinib in Mast Cell Activation Syndrome: A Retrospective Pilot Study* that was accepted.
- **Pooja Suresh, MD**, was invited to join the Abington Blood Management Committee and the Faculty Advisory Committee.
- **Dr. Suresh** was co-author of an abstract presented at the San Antonio Breast Cancer Symposium.
- **Joanna Rodriguez, MD**, was named Co-chair of

the Jefferson Abington Hospital Coagulation Committee.

- **Amy MacKenzie, MD**, piloted a trial to assess feasibility of the practical geriatric assessment. She served as co-primary investigator.
- **Dr. MacKenzie** worked with **Drs. Kuang Yi Wen, Kristine Swartz, and Andrew Chapman** to pilot the use of the practical geriatric assessment in a busy oncology clinic. This was rolled out to the center city campus and Asplundh Cancer Pavilion.
- **Dr. MacKenzie** gave two poster presentations at the International Society of Geriatric Oncology meeting in Ghent, Belgium. One was with the Jefferson Geriatric Oncology Center of Excellence research team entitled *Development and Evaluation of a Patient-Reported G8 Screening Tool on Epic MyChart for Older Cancer Patients* and the other was with the Cancer and Aging Research Group, an advocacy special interest group, entitled *Provider Communication, Referrals About Treatment Costs and*

FACULTY

Joanna Rodriguez, MD
Clinical Assistant Professor
Pooja Suresh, MD
Clinical Assistant Professor

ADVANCED PRACTICE CLINICIANS

Meghan Coleman, DNP, CRNP
Sarah Daniels, CRNP
Colleen Erb, CRNP
Dana Liskova, CRNP
Karon Martyn, CRNP
Aileen Owens, CRNP
Vadim Selyukov, CRNP
Dana Wynne, CRNP

Their Association With Financial Well-Being Among Older Adults With Cancer.

- **Clinical Lead**
Colleen Erb, CRNP authored a chapter in *The Handbook of Oncologic Emergencies and Urgencies in Acute Care Nursing* entitled *Neutropenic Fever and Sepsis* published in August 2025.
- **Colleen Erb, CRNP**, also presented *Lost, Stolen, or Never Made: Anemia Workup* at the 2nd Annual Jefferson Advanced Practice Clinician Conference on Sept. 17, 2025.
- **Colleen Erb, CRNP**, is a reviewer for the Oncology Nursing Society's guidelines update on anorexia symptom management.
- **Colleen Erb, CRNP**, is also as a reviewer of oncology nursing book proposals and book reviews for Springer Publishing.
- **Meghan Coleman DNP, CRNP**, had several presentations in 2025 including one for Jefferson Health Cancer Support Services/Community Support and another for the Managing Long-Term Side Effects of Cancer



Our care team at Asplundh Cancer Pavilion celebrated five years of excellence in cancer care.

- | | | |
|---|--|--|
| Treatment Webinar in January 2025. | part survivorship series for young people with breast cancer. | <i>Post-Treatment</i> in September 2025 at the advanced practice clinicians Oncology Summit in Philadelphia. |
| <ul style="list-style-type: none"> • Meghan Coleman DNP, CRNP, served as the Program Leader for the Living Beyond Breast Cancer Program at the Asplundh Cancer Pavilion in June 2025. It is a four- | <ul style="list-style-type: none"> • Meghan Coleman DNP, CRNP, presented <i>Cancer Survivorship: Addressing the Physical, Mental and Spiritual Needs of Younger Patients</i> | <ul style="list-style-type: none"> • Meghan Coleman, DNP, CRNP, received the 2025 Advanced Practice Provider |

Oncology Summit (APPOS) Advanced Practice Provider MVP of the Year Award in recognition of her outstanding mentorship, patient advocacy, and commitment to compassionate care.


- **Karon Martyn, MSN, ANP-BC, AOCNP**, conducted a peer review for the Advanced Practitioner Society for Hematology and Oncology's Advanced Practitioner Onboarding Course. Her review included

Module 1: Introduction to Oncology and Module 9: Late and Long-Term Toxicities and Management.

- **Karon Martyn, MSN, ANP-BC, AOCNP**, was a moderator for a panel discussion entitled *Optimizing*

Mental Health in the Cancer Patient: Meeting the Unmet Care Gap at the Advanced Practice Providers Oncology Summit on September 19, 2025. Martyn has served on the APPOS planning committee since 2017.

Figure 19: 2024 Jefferson—Abington Hospital and Asplundh Cancer Pavilion Top Five Cases



Jefferson Einstein Philadelphia Hospital

Jefferson Einstein Philadelphia Hospital provides multidisciplinary oncology, hematology, and radiation oncology services across North and Northeast Philadelphia. In 2025, the division advanced clinical, academic, and research efforts through fellowship training, multidisciplinary programs, expanded clinical trials, and closer collaboration with SKCCC. These efforts reflect a commitment to high-quality care and access to advanced therapies.

The Jefferson Einstein Philadelphia Medical Oncology and Hematology Division, along with the Radiation Oncology Section, serves the clinical needs of a community that spans from Northeast Philadelphia, with a cancer facility at the Jefferson Einstein Center One campus, to North Philadelphia, with a Cancer Center located at the Jefferson Einstein Philadelphia Hospital campus.

The largest site of activity is the Jefferson Einstein Philadelphia Hospital campus in North Philadelphia, where we serve one of the most diverse and disadvantaged populations in the United States.

Einstein is considered a private healthcare safety-net hospital, bearing a large share of responsibility for caring for the poor as measured by services to Medicaid, Medicare, SSI, and uninsured patients. More

than 87% of the patients at Einstein are covered by Medicare, Medicaid or are uninsured. We have a dual reporting structure as we are under the Sidney Kimmel Comprehensive Cancer Center and the Department of Medical Oncology at Jefferson; and are part of the Department of Medicine at Jefferson—Einstein.

The Medical Oncology and Hematology Faculty are responsible for providing clinical care in a multidisciplinary environment, as well as making an academic commitment to our Hematology-Oncology Fellowship Program and the Internal Medicine Residency Program at Einstein.

The Fellowship Program graduated two fellows again in 2025. The faculty have won multiple internal teaching awards over the years. They serve as mentors to the residents. Multiple residents have achieved fellowship positions across

the country, including one position at Queen's University in Kingston, Ontario, Canada for 2026. We also filled the two positions in our program. The Fellows and Residents, mentored by the faculty, have presented their work at multiple meetings, including ASCO and ASH in the current year.

Also in the current year, **Gabor Varadi, MD**, and **John Leighton, MD**, were nominated by the House Staff for Faculty Teaching Awards. **Dr. Varadi** was the Jefferson Einstein Philadelphia Internal Medicine Faculty Member of the Month in



John C. Leighton, Jr., MD

PHYSICIANS

John C. Leighton, Jr., MD

*Vice Chair, Medical Oncology,
Jefferson Einstein Philadelphia
Hospital*

*Medical Director, Oncology,
Medical Oncology
Hematology Associates—
Einstein*

Clinical Associate Professor



Zachary Cohn, MD

Claudia Dourado, MD

Clinical Assistant Professor

Ryan Mayo, MD

Alankrita Taneja, MD

Gabor Varadi, MD

Clinical Assistant Professor

ADVANCED PRACTICE CLINICIANS

Tara Burlingame, CRNP

Gloria Jackson, DNP, CRNP

April 2025. **Dr. Leighton** was also appointed chair of the annual meeting planning committee for the Pennsylvania Society of Hematology and Oncology's 2025 state meeting and serves as a current board member.

There are six board-certified or board-eligible hematologists and oncologists responsible for the clinical, academic, and research mission of the Philadelphia campus. Three physicians, **John Leighton, Jr., MD**, **Claudia Dourado, MD**, and **Gabor Varadi, MD** have academic appointments through the Sidney Kimmel Medical College. We are one of the busiest hematology-oncology programs from a clinical perspective, treating patients with numerous medical and psychosocial comorbidities.

Common cancers that we treat are colon, breast, lung, liver, prostate, and multiple myeloma. We see approximately 60% classical hematology patients, ranging from iron deficiency anemia to complicated cases of hemophagocytic syndrome and TTP, that are managed internally. More than ten multidisciplinary tumor boards are held across our campuses, providing

collegial and educational forums that support optimal multidisciplinary care for our patients. The group has also been more active in the SKCCC Multidisciplinary Groups.

Jefferson Einstein Philadelphia Hospital has developed a Cardio-Oncology Program over the past year and established a Psycho-Oncology Program in collaboration with the Department of Psychiatry. A collaboration with the Geriatric Division to conduct geriatric assessments on all eligible patients was launched in 2025.

Other important endeavors include:

- Multidisciplinary Psychosocial Tumor Board held weekly to review patients with significant medical and socio-economic challenges
- Rapid discharge program that brings newly diagnosed cancer patients into the Cancer Center within a week of hospital discharge in order to expedite their workup and treatment, and
- Monthly Molecular Tumor Board in which cases with treatment defining molecular tumor alterations

are discussed in a multidisciplinary setting.

The Jefferson Einstein Philadelphia practice has also begun participating in the Same Day Next Day program of SKCCC, which enables rapid evaluation and management for patients presenting to their primary physician or the emergency room with a high probability of malignancy.

In partnership with the team from SKCCC, we administered the first bispecific antibodies for cancer at our site in 2025.

Our group demonstrated a greater commitment to clinical research in 2025, thanks to the support of SKCCC. We remain involved in research projects with our fellows and students. We reopened our research program with the support of the Clinical Trials Office at the SKCCC and Jefferson's Department of Urology.

We enrolled 40 patients in clinical trials in 2025. Our highest-accruing trials included:

- Partnership with the Division of Population Science focused on electronic patient-reported outcome assessments in patients with multiple myeloma, and

- Investigator-initiated trial through Merck evaluating educational models for adherence to oral antineoplastic medications.

Multiple myeloma is one of the six most common malignancies at our site, and we have recruited a faculty member with a strong interest in this area. We plan to open clinical trials for patients with multiple myeloma.

We hope to establish a strong relationship with the hospitalist program at Jefferson Einstein Philadelphia Hospital in 2026. This would support continuity of care for patients during hospitalization and provide greater outpatient access to our hematologist-oncologists.

Due to our limited access to Jefferson medical students, we do not have as many faculty appointments as we would like. We are seeking opportunities to enable each Einstein faculty member to become a faculty member of the Sidney Kimmel Medical College.

In the coming years, we are committed to providing the highest quality care to the population we serve and growing our practice within North Philadelphia.



Dr. John Leighton spoke at the Iris Lee Schwartz Cancer Survivors Day at Jefferson Einstein Philadelphia Hospital which was held Friday, June 6, 2025. The event brought together cancer survivors, families, caregivers, and care teams for a meaningful celebration of strength, resilience, and compassionate cancer care at Jefferson Einstein Philadelphia Hospital.

We also hope to bring more clinical trials to our patients, improve the identification of tumor-specific biomarkers for each patient, and expand access to state-of-the-art therapies, beginning with bispecific antibodies and ultimately cellular therapies.

One of the 2025 highlights at Jefferson Einstein Philadelphia Hospital was the Iris Lee Schwartz

Cancer Survivors Day held on Friday, June 6, 2025, to honor and celebrate cancer survivors, their families, caregivers, and the care teams who support them.

Dr. Leighton spoke at the event, helping to recognize the strength, resilience, and hope of those affected by cancer while reaffirming their commitment to compassionate, patient-centered oncology care.

Dr. Leighton was appointed chair of the annual meeting planning committee for the Pennsylvania Society of Hematology and Oncology's 2025 state meeting. He is also a current board member.

Jefferson Einstein Montgomery Hospital

Jefferson Einstein Montgomery Hospital plays an important role in delivering oncology and hematology care across Montgomery County. In 2025, the division strengthened its clinical, academic, and research efforts through multidisciplinary care, fellowship training, expanded clinical trial activity, and collaboration with SKCCC. Its work reflects a continued commitment to high-quality care and broader access to advanced therapies for the population it serves.

Sidney Kimmel Comprehensive Cancer Center at Jefferson Einstein Montgomery Hospital (JEM) continues to provide an important access point for cancer care for patients from northern Montgomery County and points north and west. 2025 was a year filled with growth for our site and our practice. The SKCCC practice at JEM was revitalized in 2025 with the addition of vital staff and providers.

In 2025, we increased the medical oncology physicians from four to five members, increasing our capacity and access for patients. We were very proud of our medical oncologist, **Mitchell Goldstein, MD**, who was also recognized with the John McCloud Award for Connection, Compassion and Humanism.

Continued growth in our practitioner ranks included

the addition of two clinical nurse practitioners (CRNPs) to offer extended patient physician practice support increasing our total care providers to seven.

We also expanded our on-site radiation oncology services to include a third clinician and support staff in the same building, improving convenience for patients who require radiation during chemotherapy. The surgical and diagnostic teams also expanded with the addition of two GI/colorectal surgeons and an interventional pulmonologist.

During 2025, we expanded our patient navigation team and added a dietitian to our support staff. The program also provides on-site palliative care and cancer genetics counseling. Patients who need assistance with financial concerns are also

supported by our financial counselor. We offer patient support groups and a bi-monthly survivorship series. Our nurses have been recognized for their teamwork, leadership and compassion.

Our site is also very involved in education. Staff gave several lectures on cancer prevention to local community groups, including topics such as lung cancer screening. Staff also held site-specific educational events focused on breast, lung, and colorectal cancer. Cancer screening events for breast and skin cancer were also well attended.

At Jefferson Einstein Montgomery, we have seen a significant increase in the need for our services in the northwest suburbs. We look forward to continued growth in 2026 to help meet those needs.

PHYSICIANS

Tracey L. Evans, MD

*Director of Clinical Operations,
Jefferson Einstein—
Montgomery*



Minal Dhamankar, MD

Tracey Evans, MD

Mitchell Goldstein, MD

Felice Lepar, MD

Mark Morginstin, DO

ADVANCED PRACTICE CLINICIANS

Ashley Yonks, CRNP



Jefferson Einstein Montgomery Hospital hosted community outreach and education events throughout the year to share resources and support cancer prevention, treatment and survivorship efforts in Montgomery County.



(L) Baligh Yehia, MD, President, Jefferson Health, along with Jefferson Einstein Montgomery Hospital team members joined the Philadelphia Eagles at Lincoln Financial Field for Jefferson Health's "Every Catch Matters" cancer screening awareness effort, highlighting early detection, health education, and preventive care.

Jefferson–Northeast

Sidney Kimmel Comprehensive Cancer Center at Jefferson–Northeast marked a year of significant progress across clinical care, infusion services, supportive resources, research, and education. With expanded staffing, new clinical spaces, broader specialty infusion access, and growing clinical trial activity, Jefferson–Northeast continues to strengthen comprehensive oncology and hematology services for patients across Northeast Philadelphia and Bucks County.

As we complete our fifth year, SKCCC at Jefferson–Northeast continues to grow and expand our care for communities across the region. Patients throughout Northeast Philadelphia and Bucks County have never had better access to high-quality, convenient, and comprehensive oncology and hematology services.

Our team has expanded to 10 physicians and 6 nurse practitioners, allowing us to meet the increasing needs of the Northeast

region. This growth includes **Kathleen Degen, MD**, an attending physician at Jefferson–Northeast, who



Kathleen Degen, MD

began seeing breast cancer patients at the Honickman

Center on October 1, 2025. Her expanded role further strengthens collaboration across the enterprise and improves access to specialized breast cancer care for patients across Jefferson.

This year, we also reached an important milestone with the completion of six new examination rooms at the Torresdale campus. This expansion enables us to see more patients while creating space for supportive services, such as outpatient



The Sidney Kimmel Comprehensive Cancer Center opened a new medical oncology suite at Jefferson Bucks Hospital. The event was marked with a ribbon cutting on Feb. 26, 2025.

PHYSICIANS

Marcia Brose, MD, PhD

*Vice Chair, Medical Oncology, Jefferson–Torresdale
Regional Chief, Cancer Services, Sidney Kimmel Comprehensive Cancer Center
Health System Leader, Community Cancer Research, Sidney Kimmel Comprehensive Cancer Center
Chair, Hematology/Oncology, Jefferson–Torresdale
Professor*



Rakesh Biswas, MD

Kathleen Degen, MD

Jennifer Hong, MD

Clinical Assistant Professor

Felice Lepar, MD

Reddy Raghava Levaka, MD, FACP

Vladimir Limonnik, MD

Jinyu (Byron) Lu, MD

Lewis Rose, MD

Associate Professor

Jeffrey Stevens, MD



Dr. Marcia Brose (right) and staff at the opening of the new SKCCC at Jefferson Bucks Hospital

palliative care, which is now offered directly within our clinics.

One of our greatest achievements this year was the expansion of infusion services to the Bucks campus. We opened a state-of-the-art infusion center spanning 8,760 square feet. The Center features six examination rooms and 12 infusion bays, bringing high-quality infusion care closer to home for patients in the Bucks County region.

Our supportive teams including nutrition, navigation, pharmacy, financial counseling, and social work, developed integrated workflows to deliver seamless, transformative care across all sites. We also have integrated delivery of bispecific antibody treatment for small cell lung cancer, a treatment that historically has only been available at

academic centers due to the complexity of the monitoring required.

Given the success of this program we expect to expand this program more in the coming year. See figure 20 on the next page.

In keeping with our commitment to the community, we have focused not only on oncology care but also on providing infusion services for a wide range of specialties, including neurology, rheumatology, gastroenterology, hematology, pulmonology, and infectious diseases. These services offer patients convenient, local access to care delivered by compassionate, highly trained staff.

Beyond medical treatment, we recognize that many patients face challenges related to basic needs such as food insecurity. Our patient food pantry continues to provide

nutrition and support to those who need it most. Additionally, in our ongoing effort to promote health and early detection, we hosted screening events at all three Jefferson–Northeast hospital campuses this year, strengthening our connection to the communities we serve.

Clinical Research at Jefferson–Northeast has experienced significant expansion this year, marked by the initiation of 16 new clinical trials spanning various phases and disease areas, with an additional 8 trials currently in the pipeline. Over the past year we have successfully enrolled 13 patients and facilitated the referral of several more to our colleagues at Center City.

Several physicians from our northeast campus have also assumed roles as principal investigators for enterprise-wide trials.

Notably, we have also initiated and are the leads for treatment trials that are not available at Center City, and we have expanded our research portfolio to include clinical trials involving thoracic surgery.

We continue to be a very active teaching site for medical students, residents and fellows in the community. We supervise medical students (several a month) from local programs

ADVANCED PRACTICE CLINICIANS

Elizabeth Thornton,
Lead CRNP
Gabrielle D. McCarraher,
CRNP
Nicole McCole, CRNP
Christian Price, CRNP
Rachel Weeks, CRNP
Amy Young, CRNP



The Jefferson—Northeast Team

such as the Philadelphia College of Osteopathic Medicine and the Lake Erie College of Osteopathic Medicine. Medical students from farther away choose our site for elective rotations.


We continue to teach required rotations for 120 emergency department, internal medicine and

family medicine residents at Jefferson—Northeast Hospitals, who learn about cancer in the outpatient setting.

Furthermore, we have continued our active monthly grand rounds series bridging community cancer care with expertise from our colleagues in Center City. This continues to be a

very successful series which offers CME and is regularly attended by up to 60 people in person and another 60 people virtually each month.

Figure 20: 2024 JNE Top Five Cases



Jefferson–New Jersey

Over the past year, SKCCC at Jefferson–New Jersey has experienced meaningful growth across leadership, staffing, clinical services, research, and patient care access. With expanded provider recruitment, new programs, renewed clinical trial activity, and the upcoming opening of the Cherry Hill cancer facility, the practice is well positioned to strengthen oncology care for patients throughout Camden and Burlington counties.

The past year has been a year of change and growth for JNJ SKCCC. We had a change in our office leadership with members of our practice assuming new roles in the positions of cancer center director, vice chair, director of clinical operations, nurse manager, assistant nurse manager and practice manager.

We had continued recruitment with two physicians starting with our practice in September. We have recruited two new physicians to begin in August 2024 for a total of nine physicians. We continue to grow our nurse practitioner program and have added an inpatient nurse practitioner along with additional nurse practitioners in the office.

We have expanded our practice at Cherry Hill. We have been treating patients in a temporary office space with three exam rooms and seven infusion bays. We are expanding the temporary infusion space to nine bays.

We have expanded our programs to include neuro-oncology with Dr. Alnahhas, from the Center City office, seeing patients in our office and currently in discussion with Dr. Gergis to expand our bone marrow transplant and cellular therapy evaluation program. See figure 21 on the next page.

We have restarted our clinic trials program with the hiring of a project manager, research nurse and data manager. We have been able to enroll 21 patients on trial since March 2023.

Our largest goal is to open and staff our new cancer facility in Cherry Hill. This will provide us with a more competitive position to serve Camden and Burlington counties. We anticipate adding our clinical trials team to this site and we look forward to two new physicians joining the practice in August 2024 to provide more expertise in genitourinary and thoracic oncology. We have been

working with Dr. Zibelli to create a rapid access anemia clinic which will service a large population of patients from multiple medical disciplines. We will be increasing our education program to include rotations for students, residents and fellows and exploring with the hospital to create an inpatient oncology service.

PHYSICIANS

Anthony Scarpaci, MD

*Vice Chair, Medical Oncology,
Jefferson–New Jersey*




Steven Borson, MD
Ashwin Chandar, MD
Yvonne Dansoa, MD
Andres Ferber, MD
Eduardo Fernandez, MD
Zachary French, MD
Andrew Iskandar, MD
Aziz Nazha, MD
Michael Rotkowitz, MD

ADVANCED PRACTICE CLINICIANS

Johanna Cruz, CRNP
Amber DeLecce, CRNP
Maria Livecchi, CRNP
Courtney McAnally, CRNP
Latifah Nelson, CRNP
Lori Napravnik, CRNP
Margaret O'Neill, CRNP

Figure 21: 2025 Jefferson–New Jersey Top Five Cases



Lehigh Valley Topper Cancer Institute

Lehigh Valley Topper Cancer Institute, part of Jefferson Health, completed its first full year as part of the Jefferson enterprise, marking a period of remarkable growth. Now serving more than one million patients across seven regional cancer centers, the Cancer Institute expanded its clinical team, advanced cellular therapy and clinical trial access, and deepened its commitment to patients, education, transformation, and community engagement throughout the Lehigh Valley.

OVERVIEW

Lehigh Valley Topper Cancer Institute is comprised of seven regional cancer centers throughout eastern Pennsylvania:

- **Lehigh Valley Hospital (LVH)—Cedar Crest,** Allentown, PA
- **LVH—Muhlenberg,** Bethlehem, Pa.
- **LVH—Hecktown Oaks,** Easton, Pa.
- **LVH—Pocono,** East Stroudsburg, Pa.

- **LVH—Carbon,** Lehighton, Pa.
- **LVH—Schuylkill,** Pottsville, Pa.
- **LVH—Hazleton,** Hazleton, Pa.

The Cancer Institute has successfully completed its first full year as part of the enterprise, establishing itself as an integral component of our organization. Our clinical sites now serve a population of more than one million patients, and we continue to experience sustained growth

across clinical volumes, analytic cases, and service expansions. This year marks a period of unprecedented progress and achievement for the Cancer Institute.

See figures 22-25 on pages 79-80.

Our network of cancer centers serves a diverse range of communities, and we remain committed to meeting their growing needs. This year, we strengthened our team by adding several physicians and advanced practice clinicians (APC),

FACULTY

Suresh G. Nair, MD

*Physician in Chief, Lehigh Valley Topper Cancer Institute
Vice Chair, Medical Oncology, Jefferson Lehigh Valley
Regional Chief, Cancer Services, Sidney Kimmel Comprehensive Cancer Center
Medical Director, Kelly Center for Personalized Immunotherapy
Clinical Assistance Professor, Thomas Jefferson University
Chair, ABIM Medical Oncology Board*



Gabor Varadi, MD

Clinical Assistant Professor

Sheikh A. Ali, MD

Pocono

Mariette Austin, MD, PhD

Hecktown Oaks

Dillon Cason, MD

Cedar Crest/Carbon

Misbat Chaudry, MD

Cedar Crest/Schuylkill

Robert Decker, MD

Hazleton

Roberto Fratamico, MD

Carbon/Cedar Crest

Eliot Friedman, MD

Cedar Crest

Ranju Gupta, MD

Muhlenberg/Hecktown Oaks

Zeeshan Hafeez, MD

Muhlenberg

Harvey Hotchner, MD

Hazleton

Mohammad Kazemi, MD

Cedar Crest

Virtual Tour – Lehigh Valley Topper Cancer Institute



John and Dorothy Morgan Cancer Center



Cancer Center at Lehigh Valley Hospital-Muhlenberg



Dale and Frances Hughes Cancer Center



Cancer Center at Lehigh Valley Hospital-Hazleton



Cancer Center at Lehigh Valley Hospital-Hecktown Oaks



Cancer Center at Lehigh Valley Hospital-Carbon



Cancer Center at Lehigh Valley Hospital-Schuylkill

bringing our department to 32 physicians and 26 APCs. We also expanded inpatient coverage to include 24/7 APC support, enabling the growth of our cellular therapy program.

Recognizing the unique geography of our region, we have implemented cross-site physician coverage to ensure patients receive expert care closer to home. All clinicians maintain subspecialty expertise, including five dedicated exclusively to benign and malignant hematology. As part of our commitment to innovation, we have extended clinical trials to regional sites, improving access to leading-edge therapies within local communities.

This year, we welcomed a new gynecologic oncologist who administers chemotherapy in our hematology/oncology clinic at LVH–Cedar Crest and launched our first GOG trial. Additionally, our faculty includes a board-certified neuro-oncologist, further enhancing our comprehensive care capabilities.

PROMOTIONS

- **Bradley Lash, MD** - Promoted to Chief, Division of Hematology/Oncology, LVTCI
- **Michele Yadush, PA-C** - Promoted to

lead APC, the Cancer Institute

- **Maged Khalil, MD** - Named Practice Leader for GI malignancy and Director of Research, Topper Cancer Institute
- **Robert Decker, MD** - Named Physician Lead, LVH–Hazleton and LVH–Schuylkill
- **Ahmed Nadeem, MD** - Named Wellness Officer of the Cancer Institute
- **Ranju Gupta, MD** - Elected President of the Medical Staff at LVHN

NEW PROVIDERS

PHYSICIANS

- **Christine Kurian, MD** – Hematology/Oncology,



Christine Kurian, MD
LVH–Hecktown Oaks

- **Andrea Rivera, MD** – Hematology/Oncology, Cell Therapy, LVH–Cedar Crest
- **Kidist Tarekegn, MD** – Hematology/Oncology, LVH–Cedar Crest and LVH–Pocono



Andrea Rivera, MD



Kidist Tarekegn, MD

ADVANCED PRACTICE CLINICIANS

- **Kajal Desai, PA-C**, Inpatient Hematology/Oncology. LVH–Cedar Crest
- **Nidhi Kaneria, PA-C**, Inpatient Hematology/Oncology, LVH–Cedar Crest
- **Anna Roundtree, CRNP**, Nocturnist, Inpatient Hematology/Oncology, LVH–Cedar Crest
- **Marlee Guinness, CRNP**, Nocturnist, Inpatient Hematology/Oncology, LVH–Cedar Crest
- **Tyler Fornwalt, CRNP**, Hematology/Oncology, LVH–Pocono

FACULTY

- Maged Khalil, MD**
Cedar Crest
- Rachel Kinney, DO**
Pocono/Cedar Crest
- Christine Kurian, MD**
Hecktown Oaks
- Nicholas Lamparella, DO**
Cedar Crest
- Bradley Lash, MD**
Cedar Crest/Pocono
- Simi Masand Rai, MD**
Cedar Crest
- Tara Morrison, MD**
Cedar Crest
- Ahmed Nadeem, DO**
Muhlenberg
- Paul Palyca, MD**
Cedar Crest
- Don Park, MD, PhD**
Cedar Crest
- Brian Patson, MD**
Cedar Crest/Hazleton
- Dan Popescu, MD**
Pocono
- Andrea Rivera, MD**
Cedar Crest
- Muhammad Rizvi, MD**
Cedar Crest
- William Scialla, DO**
Adjunct Assistant Professor, Thomas Jefferson University
Muhlenberg
- Bhavana Singh, MD**
Pocono/Muhlenberg
- Savitri Skandan, MD**
Muhlenberg
- Sam Skariah, MD**
Muhlenberg/Cedar Crest
- Kidist Tarekegn, MD**
Pocono/Cedar Crest

- **Linda Hosler, CRNP**, Hematology/Oncology, LVH–Carbon and LVH–Hecktown Oaks
- **Amber Zukas, CRNP**, Hematology/Oncology, Cellular therapy, LLVH–Cedar Crest

COMPREHENSIVE PATIENT SERVICES

LVTCl provides full services to our patients including:

- Chemotherapy/ Biologic infusions – approximately 91,000 infusions across all sites
- Cellular therapy including CART and autologous transplantation and TIL therapy – 15 autologous transplants, 19 CART
- Clinical trial access with cooperative group studies, pharmaceutical trials and phase I trials – expanded access to all sites in our region
- Full support services including - social work, nurse navigation, dietitians, counseling services, embedded psychiatry, cancer PT/OT, lymphedema therapy, survivorship and an active volunteer program that provides support services including complementary therapies

- Cancer Genetics Program
- Comprehensive Hemophilia Treatment Center, Mid-Atlantic Region's Core Center
- Comprehensive patient blood management program to serve patients who prefer to avoid transfused blood as part of their care
- Comprehensive AYA care including faculty that are members of COG and active AYA survivorship program

We continue to uphold Jefferson's core values of engaging with grace—putting people and patients first—along with education, transformation, and community engagement.

PATIENTS FIRST

In our first year, we successfully launched a customized version of the Jefferson Same Day Next Day program across the Cancer Institute, encompassing medical oncology, surgical oncology, and gynecologic oncology. Through this initiative, patients referred to our network receive a virtual visit within 48 hours of referral, including those without a confirmed diagnosis or who self-refer. This program has significantly expanded access, reduced wait times, and improved patient

satisfaction. The program is led by our lead APC, **Michele Yadush**.

EDUCATION

Lehigh Valley Topper Cancer Institute proudly maintains a fully accredited hematology and medical oncology fellowship program with nine fellows across three years. Our physicians actively serve as educators and faculty members, contributing extensively to teaching and academic advancement. This commitment has resulted in strong academic productivity, with numerous faculty presenting posters, publishing research, and speaking at regional and national conferences.

TRANSFORMATION

The Cancer Institute has a long-standing commitment to transformative cancer care, and this year was no exception. We launched several strategic initiatives designed to expand and enhance our cancer services, including:

- First site in state of Pennsylvania and only site in the enterprise to offer histotripsy for treatment of liver tumors
- Largest and most active hepatic artery infusion program in the enterprise and one of three sites in the region

ADVANCED PRACTICE CLINICIANS

Elizabeth Aguero, PA-C
Cedar Crest

Lauren Bachman, CRNP
Schuylkill

Kristen Barrett, CRNP
Muhlenberg

Molly Breidenbaugh, PA-C
Muhlenberg

Jillian Castellani, PA-C
Muhlenberg

Mary Damweber, CRNP
Cedar Crest

Lauren Davis, PA-C
Cedar Crest

Kajal Desai, PA-C
Cedar Crest

Pollyanna Fino, PA-C
Hazleton

Tyler Fornwalt, CRNP
Pocono

April Gheller, CRNP
Pocono

Clare Grubb, PA-C
Cedar Crest

Marlee Guinness, CRNP
Cedar Crest

Linda Hosler, CRNP
Hecktown/Carbon

Carla Kalymun-Freed, CRNP
Cedar Crest

Nidhi Kaneria, PA-C
Cedar Crest

Lauren Kilduff, CRNP
Cedar Crest

Bethanie Kuna, PA-C
Pocono

Brittany Layton, PAC
Muhlenberg

Jennifer Ngo, CRNP
Muhlenberg/Hecktown

Lauren Phillips, PA-C
Pocono

Anna Rountree, CRNP
Cedar Crest

Emily Sorrentino, CRNP
Cedar Crest

Michele Yadush, PA-C
Cedar Crest

Amber Zukas, CRNP
Cedar Crest



Peter and Odete Kelly with Jefferson Leadership at The Kelly Center for Personalized Immunotherapy Announcement at the Lehigh Valley Hospital–Cedar Crest on September 30, 2025

to have the cooperative group study open for treatment of these patients

- Only site that has access to a novel pancreatic-peptide personal immunotherapy protocol and expanded access program
- Expansion of cellular therapy services including opening first cell therapy clinical trial
- Blood management program efforts resulted in LVH-Cedar Crest having the lowest blood utilization of any hospital in the Vizient database.

We have been able to advance these goals thanks to the generous support of our community. Recently, we received a transformative gift of \$12 million to establish the **Kelly Center for Personalized Immunotherapy**. This center will focus on pioneering personalized immunotherapy through translational research, the development of therapeutic cancer vaccines, and expanded access to clinical trials at the Cancer Institute. Dr. Suresh Nair has been appointed as the inaugural Medical Director, leading this groundbreaking initiative.

It is through these generous contributions—along with the support of our other donors—that we have been able to deliver groundbreaking care not only to patients in Lehigh Valley Region, but across the entire Jefferson Enterprise.

COMMUNITY ENGAGEMENT

Community engagement remains central to the the Cancer Institute mission. This year, we proudly supported numerous community initiatives and events.

The Cancer Institute offered a total of seven cancer screening events

throughout our regions, reaching a total of 322 individuals. These events are as follows:

- **Free Community Oral Cancer Screenings** in partnership with the LVHN Dental Clinic. These annual oral screenings are offered in April in conjunction with oral cancer awareness month.
 - Oral Screening at LVH–Muhlenberg with 21 in attendance
 - Oral Screening at LVH–17th Street with 19 in attendance

- Oral Screening at LVH–Hecktown Oaks Street with 30 in attendance

- **Free Community Skin Cancer Screenings** in partnership with local dermatology practices, reaching a total of 252 individuals. Skin screenings are conducted at multiple LVHN campuses to promote awareness of the importance of regular skin screening.

- Skin screening at LVH–Cedar Crest with 125 in attendance
- Skin screening at LVH–Muhlenberg with 31 in attendance
- Skin screening at LVH–Schuylkill with 42 in attendance
- Skin screening at Regional Cancer Center at LVH–Hazleton with 54 in attendance

The Cancer Institute offered a total of seven cancer survivorship events. Survivors and caregivers are invited to these events to learn about advances in research and treatment, as well as to celebrate survivorship and interact with other survivors and providers. Highlighted survivorship activities included:



Advances in Melanoma Cancer Care Survivors



Advances in Kidney Cancer Care Survivors



Advances in Pancreatic Cancer Care Survivors

- Advances in Melanoma Cancer Care with 195 in attendance
- Survivor Night at the IronPigs with 500 in attendance
- Advances in Pancreatic Cancer Care with 170 in attendance
- Advances in Kidney Cancer Care with 120 in attendance

The Cancer Institute offered various cancer prevention events throughout our regions. In addition, we sponsored and participated in numerous other cancer prevention and awareness events hosted by our community partner organizations, including American Cancer Society, Cancer Support Community of the Greater Lehigh Valley, and Blood Cancer United. Overall, the Cancer Institute offered or participated in over 15 cancer prevention events. The goal of our prevention activities is to address and educate the community on behavioral risk reduction and risk awareness in hopes of decreasing the



The Annual Topper Cancer Institute Gala, our signature community event.

likelihood of developing cancer. Highlights of our cancer prevention offerings are as follows:


- **Pink Out at the Promenade** for breast cancer prevention with 320 in attendance
- Lung Cancer Screening and Prevention Outreach at **Heritage Hill Senior Community Health Fair** in Hazleton and **Diakon Living & Learning After 50 Senior Expo** in Pottsville, reaching a

combined total of 135 individuals

The annual Topper Cancer Institute Gala remains our signature community event and one of the Lehigh Valley's premier gatherings. Dedicated to honoring patients and caregivers, the gala raises critical funds to support Cancer Institute initiatives, including the Patient Assistance Fund and, this year, the Prager Fund for non-clinical patient needs and the Counseling Fund. This

year's event celebrated numerous patients and staff as Cancer Champions and recognized the Ryan family for their generous contribution to advance our lung cancer screening program.


Figure 22: 2025 LVHN INC.* Top Five Cases



N = 2,686


*LVHN INC. is comprised of LVH–Cedar Crest, LVH–Muhlenberg, LVH–Hecktown Oaks, LVPG–Steamtown & Carbon

Figure 23: 2025 LVH–Pocono & Dickson City Top Five Cases




N = 635

Figure 24: 2025 LVH–Hazelton Top Five Cases



N = 318

Figure 25: 2025 LVH–Schuylkill Top Five Cases



N = 166

Publications

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Halabi S, Guo S, Luo B, Yu C, Knutson TP, Kobilka A, Lyman J, Beltran H, Antonarakis ES, Galsky MD, Rosenberg JE, Ryan CJ, Small EJ, **Kelly WK**, Morris MJ, Page D, Dehm SM, Armstrong AJ. Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. *Eur Urol*[25]. 2025 Aug 06.

Wilde L, Kasner M. Targeting CD47: many misses; hopeful for a hit. *Blood*[23]. 2025 Jan 30; 145(5):460-462.

Zeidner JF, Sallman DA, Récher C, Daver NG, Leung AYH, Hiwase DK, Subklewe M, Pabst T, Montesinos P, Larson RA, **Wilde L**, Enjeti AK, Kawashima I, Papayannidis C, O'Nions J, Johnson L, Dong M, Huang J, Bagheri T, Hacohen Kleiman G, Lee C, Vyas P. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. *Blood*[23]. 2025 Jul 31; 146(5):590-600.

Saifi O, Pinnix CC, Kelsey CR, Ballas LK, Milgrom

SA, Advani R, **Kasner MT**, Flampouri S, Terezakis SA, Sellmyer M, Plastaras JP, Hoppe BS. Radiate equity: the inclusion of radiation oncology and other specialties in lymphoma collaborative groups. *Lancet Haematol*[17]. 2025 Jul; 12(7):e555-e559.

Caksa S, Purwin TJ, Erkes DA, DeRosa KM, Kitterman E, Barnada SM, Stefanski CD, Wilson HP, Mersky GL, Glasheen MQ, Heilizer JS, Ajmal N, Sun Y, Chan JSY, Rui H, Chervoneva I, **Capparelli C**, Aplin AE. Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells. *Cancer Res*[16]. 2025 Jul 31.

Flynn JM, Thadani N, Gallagher EE, Azzaro I, Bodnar CM, McCarty CP, Romano G, Webster MR, **Capparelli C**. Plasticity and Functional Heterogeneity of Cancer-Associated Fibroblasts. *Cancer Res*[16]. 2025 Sep 15; 85(18):3378-3398.

Ott CA, Purwin TJ, Chen PY, Chowdhury S, Mellor GL, Luo K, Mersky GL, Tiago M, Madden WD, Varney SD, Erkes DA, Lamar

J, **Capparelli C**, Bollag G, Aplin AE. Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models. *Nat Commun*[15]. 2025 Nov 05; 16(1):9655.

Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, Haj JI, Teh JL, Kadamb R, Cai W, Rosenbaum SR, Chua V, Hacohen N, Davies MA, Villanueva J, Chervoneva I, Weeraratna AT, Erkes DA, **Capparelli C**, Aguirre-Ghiso JA, Aplin AE. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. *J Clin Invest*[13]. 2025 Sep 16; 135(18).

Bewersdorf JP, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, **Keiffer G**, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong WJ, Abdel-Wahab O, Stein EM. Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.

Leukemia[13]. 2025 Mar; 39(3):765-769.

Isabelle C, Boles A, McConnell K, Keller R, Burzinski R, Hutchins Z, Calabretto G, Cheslow L, Xu J, **Chakravarti N**, **Porcu P**, Nikbakht N, **Mishra A**. CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention. *Leukemia*[13]. 2025 May; 39(5):1146-1156.

Allen PB, Goyal S, Iyer S, Talluru S, Huen A, Greenwell B, Scribner J, Paulino D, Speegle S, Baird K, Beaven A, Switchenko JM, Rangarajan S, Mehta A, O'Leary C, Case K, Adams B, Ayers A, Bhaati S, Krishnasamy S, **Porcu P**, Sethi T, Foss F, Lechowicz MJ, Rozati S. Racial Differences in Mycosis Fungoides and Sézary Syndrome: A Multicenter Cohort Study. *J Am Acad Dermatol*[11]. 2025 Sep 29.

Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, **Razzo B**, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, De Avila G, Susaniba

- Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Castaneda Puglianini O, Rossi A, Lin Y, Atrash S, Sborov D, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson LD, Lee HC, Anwer F, Ferreri CJ, Shune L. Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. *Blood Cancer J*[11]. 2025 Jun 25; 15(1):111.
- Wysota M**, Pradhan K, Jacobs S, Rosiene J, Hall C, Downward G, Halberstam Y, Shah N, Hosgood D, Shastri A. Fine particulate matter exposure is linked to worse myeloma outcomes in a diverse urban cohort. *Blood Cancer J*[11]. 2025 Jul 07; 15(1):115.
- Afrough A, Dima D, **Razzo B**, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD, Lee HC. The impact of extramedullary and paraskelatal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience. *Blood Cancer J*[11]. 2025 Nov 28.
- Razzo BM**, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, Liu Y, Sperling AS, Nadeem O, Dima D, Banerjee R, Cowan AJ, Afrough A, Anderson LD, Lieberman-Cribbin A, Kaur G, Goyal A, Atrash S, Ferreri CJ, Voorhees PM, Pasvolsky O, Lee HC, Patel KK, Julian KL, Forsberg PA, Herr MM, Chhabra S, Parrondo RD, Lin Y, Chen A, Susanibar-Adaniya SP, Khouri J, Raza S, Anwer F, Vazquez-Martinez M, Castaneda Puglianini O, Sborov DW, Davis JA, Rossi A, Shune L, Bhurtel J, Hwang WT, Hansen DK, Sidana S, Garfall AL, Richard S. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US. *Blood Cancer Discov*[11]. 2025 Jul 09.
- Razzo BM**, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, Liu Y, Sperling AS, Nadeem O, Dima D, Banerjee R, Cowan AJ, Afrough A, Anderson LD, Lieberman-Cribbin A, Kaur G, Goyal A, Atrash S, Ferreri CJ, Voorhees PM, Pasvolsky O, Lee HC, Patel KK, Julian KL, Forsberg PA, Herr MM, Chhabra S, Parrondo RD, Lin Y, Chen A, Susanibar-Adaniya SP, Khouri J, Raza S, Anwer F, Vazquez-Martinez M, Castaneda Puglianini O, Sborov DW, Davis JA, Rossi A, Shune L, Bhurtel J, Hwang WT, Hansen DK, Sidana S, Garfall AL, Richard S. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US. *Blood Cancer Discov*[11]. 2025 Aug 08:OF1-OF11.
- Lopez JS, Milhem M, Butler MO, Thistlethwaite F, Van Tine BA, D'Angelo SP, Johnson ML, **Sato T**, Arkenau HT, Edukulla R, Wustner J, Marshall S, Rodon J. Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies. *Cell Rep Med*[10]. 2025 Apr 15; 6(4):101994.
- Sacco JJ, Kirk P, Leach E, Shoushtari AN, Carvajal RD, Britton-Rivet C, Khakoo S, Collins L, de la Cruz-Merino L, Eroglu Z, Ikeguchi AP, Nathan P, Hamid O, Butler MO, Stanhope S, Ranade K, **Sato T**. Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific. *Cell Rep Med*[10]. 2025 Apr 15; 6(4):102076.
- Mastrolonardo EV, Nunes KL, Llerena P, Nikitina A, Sobol A, Scott ER, Tuluc M, Davitt CJH, Scher J, Tekumalla S, Mann D, Henao C, Jegede V, Gargano S, Harshyne LA, Alnemri A, Tyshevich A, Kushnarev V, Chasse M, Sookiasian D, Axelrod R, Zhan T, Leiby BE, Old M, Seim N, Mahoney MG, **Martinez-Outschoorn U**, Cognetti DM, Curry JM, Prendergast GC, Argiris A, South AP, Linnenbach AJ, **Johnson JM**, Luginbuhl AJ. Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res*[10]. 2025 Feb 03; 31(3):515-528.
- Saba NF, Flamand Y, Lin DT, Chung CH, McDonald MW, Flampouri S, Khan SA, Snyderman CH,

- Hanna EY, El-Sayed IH, Solares CA, Le CH, Ghaly M, Hwang PH, Shin DM, **Axelrod RS**, Ikpeazu CV, Adkins DR, Duan F, Cohen M, Samuels MA, Swiecicki PL, Subramaniam RM, Chakravarthy AB, Burtneess BA. Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. *Clin Cancer Res*[10]. 2025 Jun 13; 31(12):2339-2346.
- Shen F, Smith R, McDevitt T, Menard K, Tian S, Chu G, Chaudhary R, McCann J, Oyer H, Wang S, Max S, Francis P, **Kelly WK**, Drake CG. Human kallikrein 2: A novel lineage-specific surface target in prostate cancer. *Clin Cancer Res*[10]. 2025 Jul 08.
- Wesolowski R, Rugo HS, Specht JM, Han H, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, **Abu-Khalaf M**, Mutka SC, Suzuki S, Sullivan B, Gorbachevsky I, Layman RM. Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer. *Clin Cancer Res*[10]. 2025 Jul 25.
- Llerena P, Samarah H, Nunes K, Lin Z, Bridgham K, Tekumalla S, Jain A, Harshyne L, Shukla SK, Vathiotis I, Tuluc M, Gargano S, Eisenbrey JR, Keith S, Cognetti DM, Bar-Ad VC, Luginbuhl AJ, **Axelrod R**, Vadigepalli R, **Yang H**, Whitaker-Menezes D, Roche M, Mahoney MG, Argiris A, Solomides C, Johnson JM, Barbirou M, Miller A, South AP, Mitra R, Linnenbach AJ, **Martinez-Outschoorn U**, Curry JM. Extracellular matrix-myCAF signatures correlate with resistance to neoadjuvant aPD-L1 immune checkpoint inhibition with durvalumab + metformin in HPV+ HNSCC. *Clin Cancer Res*[10]. 2025 Sep 11.
- Sato T**, Butler MO, Piperno-Neumann S, Hassel JC, Nathan P, Shoushtari AN, Rutkowski P, Carvajal RD, Baurain JF, Schlaak M, Piulats JM, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Ikeguchi A, Joshua AM, Middleton MR, Edukulla R, Pfeiffer C, Sacco JJ. Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients. *Clin Cancer Res*[10]. 2025 Sep 12.
- Aggen DH, McKean M, Hoffman-Censits JH, Lakhani NJ, Alhalabi O, Guancial EA, **Bashir B**, Bowman IA, Tan A, Lingaraj T, Ortiz-Otero N, Bartolini W, Timothy M, Kim K, Kacena K, Santillana SS, Luke JJ. IK-175, an oral aryl hydrocarbon receptor inhibitor, alone and with nivolumab in patients with advanced solid tumors and urothelial carcinoma. *Clin Cancer Res*[10]. 2025 Nov 03.
- Zinner RG, Mastrolonardo EV, **Johnson JM**, Nunes K, Llerena P, Elliott Z, Tuluc M, Curry JM, Fundakowski CE, Yampolsky A, Goldman R, Solomides CC, Gargano SM, Naringrekar H, Harshyne L, Poller D, Leiby BE, Bar-Ad V, **Axelrod R**, Argiris A, Luginbuhl AJ, Cognetti DM. Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial. *Clin Cancer Res*[10]. 2025 Dec 12.
- Zimmerman MKA, **Wilde L**. Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon. *Am J Hematol*[9]. 2025 Feb; 100(2):298-299.
- Banerjee R, Kaur G, **Razzo BM**, Portuguese AJ, Sidana S, Richards T, Grajales-Cruz A, Richard S, Shune L, Khouri J, Dima D, Lee HC, Patel KK, Pasvolsky O, Vazquez-Martinez M, Hansen DK, Afrough A, Davis JA, Hashmi H, Atrash S, Ferreri CJ, Julian KL, Herr MM, Midha S, Costello P, Forsberg P, de Menezes Silva Corraes A, Lin Y, Cowan AJ, Anderson LD, Garfall AL. Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response. *Am J Hematol*[9]. 2025 Oct 11.
- Verma M, Davidsohn MP, Arends CM, Verma D, Sahu S, Pradhan K, Dehghani SS, Murli H, Jasra S, Aggarwal RK, Zhang H, **Wysota M**, Hosgood D, Verma A, Jaiswal S, Zou Y, Shastri A. Environmental Pollution Triggers Inflammation In Vivo and is Associated With Higher Risk MDS in an Urban Cohort. *Am J Hematol*[9]. 2025 Nov 11.
- Cunanan CJ, Sanders AB, Gallant KC, **Seedor RS**, Hartsough EJ. Functions and clinical implications of the liver microenvironment in hepatic uveal melanoma metastases. *Cancer Metastasis Rev*[8]. 2025 Oct 29; 44(4):80.
- Ruiz M, Braunstein Z, McLaughlin E, **Mishra A**, **Porcu P**, Brammer JE. Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia. *Haematologica*[7]. 2025 Apr 01; 110(4):995-998.
- Burus T, McAfee CR, Hull PC, **Leader AE**, **McNair C**. Tracking community outreach and engagement activities among National Cancer Institute-

- designated cancer centers. *J Natl Cancer Inst*[7]. 2025 Feb 01; 117(2):335-337.
- El Khoury CJ, Freedland SJ, Gandhi K, Keith SW, **Nikita N, Shaver A, Sharma S, Kelly WMK, Lu-Yao G**. Disparities in the utilization of magnetic resonance imaging for prostate cancer detection: a population-based study. *J Natl Cancer Inst*[7]. 2025 Feb 01; 117(2):270-278.
- Dimitriou F, **Orloff MM**, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. *Eur J Cancer*[7]. 2025 Jan; 214:115161.
- Wudhikarn K, Herr MM, Chen M, Martens MJ, Baird JH, Gowda L, Rangarajan HG, Abid MB, Kharfan-Dabaja MA, Williams KM, Ganguly S, Young JH, Sharma A, Fatobene G, Jain T, Kanakry CG, Modi D, Grover NS, Salem B, Batista MV, Vergidis P, Yin DE, Beitinjane AM, Kelkar AH, Nishihori T, Holter-Chakrabarty J, **Gergis U**, Smith M, El Boghdady Z, Dandoy CE, Murthy HS, Huppler AR, Perales MA, Chemaly RF, Hill JA, Riches M, Auletta JJ. Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR. *Blood Adv*[7]. 2025 May 28.
- Dima D, Afrough A, Goel U, Grajales-Cruz AF, Khouri J, Julian K, Pasvolsky O, Banerjee R, **Razzo B**, Ferreri CJ, Vazquez-Martinez MA, Davis JA, Sannareddy A, Castaneda O, Raza S, Portuguese AJ, Gaballa MR, Rana MS, Lieberman-Cribbin A, DeJarnette S, Gonzalez R, Chen A, Herr MM, Mikkilineni L, Hosoya H, Ouchveridze E, Kaur G, Rossi A, Shune L, Anwer F, Lin Y, Richard S, Sborov DW, Baz RC, Garfall AL, Lee HC, Anderson LD, Cowan AJ, Patel KK, Voorhees PM, Sidana S, Hansen DK, Atrash S, Susanibar-Adaniya SP. Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment. *Blood Adv*[7]. 2025 Jul 22; 9(14):3408-3417.
- Iyer SP, Mehta-Shah N, Advani RH, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WSS, **Alpdogan O**, Feldman TA, Camus V, Gritti G, Zinzani PL, Belada D, Mayer J, Choi I, Cheong JW, Rustia E, Fenton K, Fanale M, Savage KJ, Horwitz SM. Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma. *Blood Adv*[7]. 2025 Aug 19.
- Lawler ME, Romer-Seibert JS, Bowman MS, Mitra R, **Eischen CM**, Bowman RL, Meyer SE. TLR2 Agonism Suppresses Myeloid Leukemogenesis by Reprogramming Leukemia Stem Cells. *Blood Adv*[7]. 2025 Aug 20.
- Alberti A, Gurizzan C, Resteghini C, Trama A, Bernasconi A, Grisanti S, Zamparini M, Mohamad I, Linares Galiana I, Ozyar E, Franco P, Vecchio S, Bonomo P, Cirauqui B, El-Sherify M, Ursino S, Argiris A, Pan J, Wittekindt C, D'Angelo E, Costa L, Buglione M, **Johnson JM**, Airolidi M, Mesia R, Licitra L, Orlandi E, Bossi P, Nasopharyngeal Cancer Portal Group of Investigators. A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era. *Eur J Cancer*[7]. 2025 Sep 02; 229:115749.
- Elisei R, Wirth LJ, Capdevila J, Hoff AO, Tahara M, Sherman EJ, Hu MI, Ge MH, Wadsley J, Vaisman F, Kopeckova K, Krajewska J, Olvera D, Churchill C, Maeda P, Gilligan AM, Lin Y, Payakachat N, Robinson B, Hadoux J, **Brose MS**. Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer. *Thyroid*[6]. 2025 Aug 18.
- Rajendram P, Stephens RS, Brown ART, May HP, Nates JL, Pastores SM, Dharshan A, Gallo de Moraes A, Hensley MK, Feng L, McEvoy C, **Ibikunle S**, Beasley M, Mead E, Westin J, Kosteletzky NT, Mucha S, Mian A, Ahmed S, Tharwani A, Hill BT, Herr MM, Lin Y, Gutierrez C, and the Chimeric Antigen Receptor for the ICU (CAR-ICU) Initiative. Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU. *Crit Care Med*[6]. 2025 Dec 30.
- Loeb S, Cheng HH, Paller CJ, Weg E, **Johnson J**, Gross L, Keith SW, Russo J, Hathaway F, Rivera A, Giri VN. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. *Prostate Cancer*

Prostatic Dis[5]. 2025 Mar; 28(1):220-222.

Nixon AB, Liu Y, Yang Q, Luo B, Starr MD, Brady JC, **Kelly WK**, Beltran H, Morris MJ, George DJ, Armstrong AJ, Halabi S. Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/ prednisone with or without bevacizumab. *Prostate Cancer Prostatic Dis*[5]. 2025 Jun; 28(2):355-362.

Hassel JC, Stanhope S, Greenshields-Watson A, Machiraju D, Enk A, Holland C, Abdullah SE, Benlahrech A, **Orloff M**, Nathan P, Piperno-Neumann S, Staeger R, Dummer R, Meier-Schiesser B. Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action. *J Invest Dermatol*[5]. 2025 Mar; 145(3):559-572.e9.

Hafer R, Duong T, Yang HY, Tolotta J, Mandel JL, Banner L, **Porcu P**, Nikbakht N. The Risk of Developing Keratinocyte Malignancies in Patients with Cutaneous T-Cell Lymphoma. *J Invest Dermatol*[5]. 2025 Jun; 145(6):1523-1526.e8.

Landry I, **Binder AF**, Yorker M, Ramirez S. Redefining central nervous system

multiple myeloma: From rare phenomenon to emerging entity. *Blood Rev*[5]. 2025 Nov; 74:101343.

Williams MN, Joffe D, Mandel J, Scheppes S, Wallace M, Portocarrero C, Abinader O, Mitra R, **Mishra A**, Nikbakht N. Spatial transcriptomics uncovers unique tumor microenvironments in folliculotropic versus classic mycosis fungoides. *J Invest Dermatol*[5]. 2025 Dec 01.

Brose MS, Westphalen CB, Pan X, Bernard-Gauthier V, Kurtinecz M, Guo H, Aris V, Brett NR, Majdi A, Subbiah V, Pennell NA, Kehl KL, Drilon A. Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. *JCO Precis Oncol*[5]. 2025 Apr; 9:e2400500.

Bitting RL, **McNair C**, Wyatt AW, Vandekerkhove G, Choi T, **Leader AE**, Blanding-Godbolt J, Gross L, Hamade K, Halabi S, Giri VN. Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey. *JCO Precis Oncol*[5]. 2025 May; 9:e2400821.

Lefler DS, Elliott A, Jiang W, **Martinez-Outschoorn U**, Al-Sabah J, Freed DM, King CM, Maki RG, Riedel RF, Modiano JF, Hübschmann D, Glimm H, Fröhling S, Oberley M, Boikos SA, **Basu Mallick A**. Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in Chordoma. *JCO Precis Oncol*[5]. 2025 Jul; 9:e2500149.

Moroco AE, Nunes K, Alnemri A, Bridgham K, Llerena P, Tuluc M, Gargano S, Zhan T, Thal AG, Cognetti DM, Curry JM, **Johnson JM**, Luginbuhl AJ. Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab. *JAMA Otolaryngol Head Neck Surg*[5]. 2025 Jul 31.

Loeb S, Keith SW, Gross L, Hartman RL, Beer TM, Brierley KL, Cheng HH, Couvillon A, Dicker AP, Friedman S, Gomella LG, Karsh L, **Kelly WK**, Lallas CD, **Leader AE**, Mann MJ, Mark JR, **Mille P**, Paller CJ, Rana HQ, Sokolova AO, Trabulsi EJ, Whang YE, Giri VN. Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry. *JCO Precis Oncol*[5]. 2025 Sep; 9:e2500571.

Mastrolonardo EV, De Ravin E, Kaki PC, Estephan LE, Nunes K, Kenny H, Bridgham K, Tasoulas J, Koeneman SH, Goldman RA, Fundakowski C, Thal A, Cognetti DM, **Johnson JM**, Luginbuhl AJ, Curry JM. Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC: A Systematic Review and Meta-Analysis. *JAMA Otolaryngol Head Neck Surg*[5]. 2025 Dec 18.

Neupane M, Kumar M, Mwamufiya MA, Donnelly CM, Ibragimova A, Curcio B, Chervoneva I, Vasilevskaya I, **Silver DP**. MECP2-Dependent Cancers Can Be Targeted by Epigenetic Drugs: A New Role for Epigenetic Cancer Therapy. *Mol Cancer Ther*[5]. 2025 Dec 11.

Evans HM, Landy R, Shusted CS, Ruane B, Anderson E, Giamboy T, McMullen M, Kane GC, **Juon HS**, Barta JA. Variation in Lung Cancer Risk Distribution by Race Across Modified PLCO Risk Models Among Lung Cancer Screening Participants. *Ann Am Thorac Soc*[5]. 2025 Sep 17.

Bekadja MA, Niederwieser D, Kharfan-Dabaja MA, El Fakih R, Garderet L, Yakoub-Agha I, Greinix H, Weisdorf DJ, Galeano S, Ahmed SO, Chabanon C, Hashmi SK, Ruggeri A, **Gergis U**, Bazarbachi

- A, Hamad N, Albeihany A, Pasquini M, Hanbali A, Szer J, Kodera Y, Kumar A, Elhassan T, McLornan D, Worel N, Greco R, Mohty M, Atsuta Y, Koh M, Sureda A, Rondelli D, Aljurf M, Rasheed W. Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation. *Bone Marrow Transplant*[5]. 2025 Jan; 60(1):19-27.
- Sunbul FS, Almuqbil RM, Zhang H, Alhudaithi SS, Fernandez ME, Aldaqqa RR, Garcia VA, Robila V, Halquist MS, **Gordon SW**, Bos PD, da Rocha SRP. An improved experimental model of osteosarcoma lung metastases to investigate innovative therapeutic interventions and sex as a biological variable. *Int J Pharm*[5]. 2025 Mar 30; 673:125372.
- Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, **Gergis U**, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC. Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. *Bone Marrow Transplant*[5]. 2025 May; 60(5):632-639.
- Mastrolonardo EV, Llerena P, De Ravin E, Nunes K, Kaki PC, Bridgham KM, Amin DR, Campbell DJ, Philips R, Koeneman SH, Cognetti DM, Luginbuhl AJ, Simone NL, **Johnson JM**, Curry JM. Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types. *Cancer*[5]. 2025 Mar 15; 131(6):e35799.
- Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, **Sato T**, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. *Cancer*[5]. 2025 Aug 01; 131(15):e70022.
- Lin D**, Quan W, Garretson M, Chirikov V, Chen C, Singh P, Davis C, Sugarman R. Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results. *Gastric Cancer*[5]. 2025 Sep; 28(5):935-944.
- Logan JA, Sadhu S, Hazlewood C, Denton M, Burke SE, Simone-Soule CA, Black C, Ciaverelli C, Stulb J, Nourzadeh H, Vinogradskiy Y, **Leader A**, Dicker AP, Choi W, Simone NL. Bridging Gaps in Cancer Care: Utilizing Large Language Models for Accessible Dietary Recommendations. *Nutrients*[5]. 2025 Mar 28; 17(7).
- Bloom M, Podder S, Dang H, **Lin D**. Advances in Immunotherapy in Hepatocellular Carcinoma. *Int J Mol Sci*[4]. 2025 Feb 24; 26(5).
- Bizzaro CL, Bach CA, Santos RA, Verrillo CE, Naranjo NM, Chaudhari I, Picone FJ, Iqbal W, Blidner AG, Rabinovich GA, Fatatis A, Jacobi J, Goodrich DW, **Zarrabi KK**, **Kevin Kelly W**, Schiewer MJ, Languino LR. Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles. *Mol Cancer Res*[4]. 2025 Jun 03; 23(6):542-552.
- Zheng Y, Han J, Qu Y, Wang J, Joyce BT, Okeke E, Davwar PM, Duguru MJ, Nyam DP, Odeghe E, Oyeleke G, Lesi OA, Imade GE, Sulaimon AA, Hawkins C, Abdulkareem FB, Badmos K, Gursel DB, Wei JJ, Silas OA, Kocherginsky M, Kim KA, Sun Z, Achenbach CJ, Zhang X, **Yang H**, Sagay AS, Ogunsola FT, Murphy RL, Roberts LR, Hou L. Circulating cell-free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV-positive Nigerian population. *Int J Cancer*[4]. 2025 Oct 23.
- Woofter K, Kennedy EB, Adelson K, Bowman R, **Chapman AE**, Dixit N, Gerber R, Jefferies P, Martin E, Mulvey TM, Olsen M, O'Mahony D, Polite B, Sadeghi N, Shaw M, Skelton MR, Cox J. Oncology Medical Homes: ASCO-Community Oncology Alliance Standards. *JCO Oncol Pract*[4]. 2025 Jul 21:OP2500498.
- Kendzor DE, Davie M, Chen M, Hart J, Frank-Pearce SG, Doescher MP, Alexander AC, Businelle MS, Ogunsanya ME, **Sifat MS**, Boozary LK. Incentivizing Tobacco Helpline Engagement in Persistent

- Poverty Counties: A Randomized Trial. *Am J Prev Med*[4]. 2025 Feb; 68(2):336-347.
- Islam R, Roche ME, Lin Z, Whitaker-Menezes D, Diaz-Barros V, Serrano E, Martinez Cantarin MP, Philp NJ, **Basu Mallick A, Martinez-Outschoorn U**. TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis. *Mol Oncol*[4]. 2025 Aug; 19(8):2431-2455.
- Cunningham ML, Vasquez-Gonzalez J, Barnada SM, Tchotorlishvili S, Jones L, Maguire R, Lewis G, Rizwan K, Deng J, Koachar S, Patel D, Shankle H, Mulders T, Ajmal N, Solomides C, Alnemri ES, Alnemri TF, Shafi AA, Gomella LG, **Kelly WK, McMahon SB, Schiewer MJ**. PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer. *Mol Oncol*[4]. 2025 Sep 07.
- Nikita N**, Sun Z, Sharma S, **Shaver A**, Seewaldt V, **Lu-Yao G**. Epigenetic Landscapes of Aging in Breast Cancer Survivors: Unraveling the Impact of Therapeutic Interventions-A Scoping Review. *Cancers (Basel)*[4]. 2025 Mar 03; 17(5).
- Perez Kerkvliet CJ, Leong JY, Thompson RAM, **Zarrabi KK, Kelly WK**, Lallas C, Gomella L, Shah M. Treatment Intensification Prior to Radical Prostatectomy for Clinically Localized Prostate Cancer. *Cancers (Basel)*[4]. 2025 Jul 07; 17(13).
- Bloom M, Shaikh AR, Sun Z, **Bashir B**, Snook AE. Cancer Vaccination and Immune-Based Approaches in Pancreatic Cancer. *Cancers (Basel)*[4]. 2025 Jul 15; 17(14).
- Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, **Gergis U**, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. *Transplant Cell Ther*[4]. 2025 Aug 05.
- Shaver AL, Nikita N**, Sharma S, Keith SW, **Zarrabi KK, Kelly WK, Lu-Yao G**. The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials. *Cancers (Basel)*[4]. 2025 Aug 23; 17(17).
- Gradone A, **Bi X**, Durugu S, Bao A, **Gattas B**, Nath AD, **Filicko-O'Hara J**, O'Hara W, Storozynsky E, Grosso D, Flomenberg N, **Gergis U**. The Heart of the Matter: Cardiac Toxicity in Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide. *Transplant Cell Ther*[4]. 2025 Oct 27.
- Najjar YG, **Orloff M**, Mitchell TC, Bowles TL, Betof Warner A, Bollin K, Chandra S, Cohen JV, Eroglu Z, Funchain P, Gaughan E, Glitza Oliva I, Hsu S, Hu-Lieskovan S, Kennedy LB, Truong TG, McKean M, Mehnert J, Moon H, Tsai KK, Wilson M, Tran T, Buchbinder EI, Fecher LA, Guild S, Patel SP. Proceedings of the seventh annual Women in Melanoma Conference. *Ther Adv Med Oncol*[4]. 2025 Jun 14; 17:17588359251342039.
- Lim TL, Montazeri K, Wehrenberg-Klee E, Desilets A, **Seedor R, Orloff M, Sato T**, Caplan M, El-Ashmawy M, Izar B, Khan S, Mehmi I, Lawless A, Hong TS, Hamid O, Carvajal RD, Shoushtari A, Sullivan RJ. Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients. *Oncologist*[4]. 2025 Sep 29.
- Cappelli L, Kayne A, Newman J, Elguindy A, Epperla N, Palmer JD, **Martinez-Outschoorn U, Porcu P**, Shi W, Alnahhas I. Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression. *Neurooncol Adv*[4]. 2025; 7(1):vdaf082.
- Shaver AL**, Gandhi K, Keith SW, **Nikita N**, Yang CC, Kim FJ, **Yang H, Kelly WK**, Freedland SJ, **Lu-Yao G**. Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study. *JNCI Cancer Spectr*[4]. 2025 Sep 01; 9(5).
- Sayeed A, Garcia V, Verrillo CE, DeRita RM, Hossain MN, Krishn SR, Sey S, Shields CD, Altieri AD, Liu Q, Sossey-Alaoui K, **Kelly WK**, Languino LR. Irradiation of prostate cancer alters circulating small extracellular vesicle functions. *Sci Rep*[3]. 2025 Jul 02; 15(1):23217.
- El Khoury CJ**, Ros PR. Response to: "Letter to the Editor Re: A Systematic Review for Health Disparities and Inequities in Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis". *Acad Radiol*[3]. 2025 Nov 24.
- Hossain NM, Ahn KW, Patel J, Lian Q, Bilal Abid M, Al Nughmush A, Bacher U, **Bi X**, Hashmi SK, Hilal

- T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF. Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS. *Br J Haematol*[3]. 2025 Sep; 207(3):1011-1018.
- Bhattacharya P, Linnenbach A, South AP, **Martinez-Outschoorn U**, Curry JM, **Johnson JM**, Harshyne LA, Mahoney MG, Luginbuhl AJ, Vadigepalli R. Tumor microenvironment governs the prognostic landscape of immunotherapy for head and neck squamous cell carcinoma: A computational model-guided analysis. *PLoS Comput Biol*[3]. 2025 Jun; 21(6):e1013127.
- Sifat MS**, Boozary LK, Le TN, McQuoid J, Zaring-Hinkle B, Tonkin S, Benson L, Mao B, Ogunsanya M, Shao R, Cohn AM, Shortle A, Kendzor DE. Mental health and beliefs about abortion access following changes to reproductive healthcare laws in 2022: findings from Oklahoma. *BMC Public Health*[3]. 2025 Dec 30; 25(1):4384.
- Leader AE**, Burke-Garcia A, Afanaseva D, Cutroneo E, Selvan P, Madden K, Banks J, Sustaita-Ruiz A. Partnering with social media influencers to promote HPV vaccination in diverse communities. *Vaccine*[3]. 2025 Apr 19; 53:127085.
- Zager JS, **Orloff M**, Ferrucci PF, Choi J, Eschelmann DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheeler M, Ottensmeier CH. An Open-label, Randomized Study of Melphalan/ Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma. *Ann Surg Oncol*[3]. 2025 Jul; 32(7):4976-4988.
- Altieri A, Reilly SP, Mansalay A, Khoo AS, Johnson N, Khan ZK, **Leader A**, Jain P, **Porcu P**. HTLV-1 and ATLL: Epidemiology, Oncogenesis, and Opportunities for Community-Informed Research in the United States. *Viruses*[3]. 2025 Sep 30; 17(10).
- Ben-Arye E, Malin MA, Gressel O, Keshet Y, Carlson LE, Samuels N, **Lopez AM**, Balneaves LG, David A, Frenkel M, Schiff E. A national multi-disciplinary integrative oncology training program in Israel: Trainee perspectives. *J Pain Symptom Manage*[3]. 2025 Dec 20.
- Kemp M, Rising KL, Laynor G, Miao J, Worster B, Chang AM, Monick AJ, Guth A, Esteves Camacho T, McIntosh K, Amadio G, Shughart L, Hsiao T, **Leader AE**. Barriers to telehealth uptake and use: a scoping review. *JAMIA Open*[3]. 2025 Apr; 8(2):ooaf019.
- Stopeck AT, **Abu-Khalaf M**, Borges V, Chmielowski B, Rao R, Xie B, Dudek AZ, Mina L, O'Shaughnessy J, Chisamore M, Mattson P, Gargano M, Cox J, Osterwalder B, Drees J, Harrison B, Chan ASH, Qiu X, Ottoson N, Bose N, Uhlik M, Graff J, Iglesias J. Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy. *J Immunol*[3]. 2025 Jul 01; 214(7):1529-1538.
- Holloway RW, Temkin SM, **Gordon SW**, Gupta S, Jada SR, Ahmad S, McGuire WP. A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol in Patients with Recurrent Platinum-Resistant Ovarian Cancer. *Curr Oncol*[3]. 2025 Sep 24; 32(10).
- Chavez-Yenter D, Fetzner D, Egleston B, Domchek S, Fleisher L, Wagner LI, **Wen KY**, Karpink K, Gutstein L, Posen S, Selmani E, McLeod B, Anantharajah A, Brown S, Cacioppo C, Cappadocia J, Ebrahimzadeh JE, Falcone D, Howe S, Langer C, McCarthy-Wood B, Weinberg M, Bradbury AR. The MyCancerGene study: a hybrid type 1 effectiveness-randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testing. *BMC Cancer*[3]. 2025 Oct 24; 25(1):1642.
- Chan A, Nasr R, Arcos D, Kagramanov D, Asuzu C, Bao T, Cheung YT, Kwon JH, Lacey J, Lee RT, Lustberg M, Ohaeri BM, Rao S, Soto-Perez-de-Celis E, Witt CM, **Lopez AM**. Evaluation of integrative oncology modalities for symptom management: a MASCC/SIO global survey. *BMC Complement Med Ther*[3]. 2025 Nov 03; 25(1):406.
- Palecki J, Tucker M, Bernstein A, Melby G, Zhan T, **Micaily I**. HIV and lung cancer: a single cancer center experience. *Front Oncol*[3]. 2025; 15:1600709.
- Rshaidat H, Mack SJ, Koeneman SH, Martin J, Whitehorn GL, Madeka I, **Gordon SW**, Okusanya OT. The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer. *Clin Lung*

Cancer[3]. 2025 Mar; 26(2):131-139.

Mikkilineni S, Pineda-Reyes JP, **Wilde L, Ferber A**, Wang ZX, Peiper S, Uppal G, Gong J, Liu J. Case Report: Myeloid neoplasms with the t(3;12)(q26.2;p13.1)/MECOM-ETV6 translocation: report of two new cases and review of the literature. *Front Oncol*[3]. 2025 Apr 4; 15:1526044.

Palecki J, Tucker M, Bernstein A, Melby G, Zhan T, **Micaily I**. Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in Philadelphia. *Clin Lung Cancer*[3]. 2025 Sep; 26(6):e409-e412.

Katcher JG, Shusted CC, Bhatt P, Ruane BM, Markle J, Kane GC, **Wen KY, Juon HS**, Barta JA. Brief Report: Lung Cancer Diagnoses among Lung Cancer Screening Program Participants With Family History of Lung Cancer. *Clin Lung Cancer*[3]. 2025 Nov 07; 27(1):34-37.

Leader AE, Pham K, Cianci N, Knapp H, Doka F, Barron S, Kolesnikov O, DeHoratius J, Bradley K, Robles L, Giamboy R, Dahlgren O, Gomella LG. Evaluating the impact of a community-based prostate cancer screening program. *Arch Public Health*[3]. 2025 Dec 24; 83(1):305.

Wen KY, Palmisiano N, Smith R, Slamon R,

Keiffer G, Fidler C, Kasner M, Wilde L. A smart pill bottle and text messaging intervention for promoting medication adherence in patients with chronic myeloid leukemia: a pilot study of txt4 TKI. *Support Care Cancer*[3]. 2025 May 24; 33(6):498.

Yuan L, Kulkarni M, Chiswick E, Koh C, Sandy P, Nabhan S, Sherman W, Johnson M, Wang J, Falchook G, **Johnson J**, Winter C, Gardner H, Chakravarty A, Stoddard M. A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect level. *Br J Clin Pharmacol*[3]. 2025 Sep; 91(9):2555-2566.

Terai M, Seedor R, Ashraf U, Hubbard G, Koshkin S, **Orloff M, Sato T**. Short Report: The Variants in CHEK2 in Metastatic Uveal Melanoma. *J Clin Med*[2]. 2025 Apr 18; 14(8).

Shao YF, Baca Y, Hinton A, Xiu J, VanderWalde A, Hadfield M, Park SJ, Darabi S, **Sato T**, Moser JC. Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint Inhibitors. *J Immunother*[2]. 2025 Jun 01; 48(5):189-195.

Kuo C, Ahn LH, **Sifat M**, Green KM. Does parental racial socialization protect Black youth from the

impact of racism on problematic substance use over the long term? *Cultur Divers Ethnic Minor Psychol*[2]. 2025 Jul 28.

Alfaro MKC, Shusted CS, Giamboy T, Kane GC, Evans NR, Ruane BM, Gatson-Anderson E, Muse E, McMullen M, Kinsey AM, Murray S, **McNair C**, Barta JA. Using an Integrated, Digital Framework to Standardize and Expand a Multisite Lung Cancer Screening Program. *JCO Clin Cancer Inform*[2]. 2025 Jun; 9:e2400322.

Tachibana M, Horwitz S, Jacobsen E, Foss F, Allen P, **Porcu P**, Feldman T, Ruan J, Brammer JE, Wang J, Inaba S, Iko Y, Nakajima K, Kakurai Y, Kitami N, Chen Y, Lau Y. Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma. *Clin Transl Sci*[2]. 2025 Nov; 18(11):e70330.

Karp DN, Hamade K, **McNair CM, Leader AE**. Development of a Composite Measure to Identify Priority Areas of Need for Cancer Screening Interventions. *JCO Clin Cancer Inform*[2]. 2025 Dec; 9:e2500132.

Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A,

Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Gschnell M, Dummer R, Arance A, Fenwick SW, Sacco JJ, John J, Wheeler M, Ottensmeier CH. Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma. *J Cancer Res Clin Oncol*[2]. 2025 Dec 29; 152(1):25.

Zuber C, Swartz K, **Chapman AE**, Rhodes L, Zhan TT, **Wen KY**. Evaluation of the Distress Thermometer in older patients with cancer. *J Geriatr Oncol*[2]. 2025 May; 16(4):102221.

Wang L, Lu Q, Li R, Harrison TB, Jia H, Huang M, Dowst H, Zhang R, **Badr H**, Fan JW, Liu H. Understanding Cancer Survivorship Care Needs Using Amazon Reviews: Content Analysis, Algorithm Development, and Validation Study. *JMIR Cancer*[2]. 2025 Sep 23; 11:e71102.

Leader AE, Loeb S, Selvan P, Hunter A, Hartman R, Keith SW, Giri VN. A Social Media Campaign and Web-Based Survey About Prostate Cancer Genetics: Mixed Methods Study. *JMIR Cancer*[2]. 2025 Oct 14; 11:e69787.

Waguespack SG, Cabanillas ME, Bernard-Gauthier V,

- Assar N, Bloom G, Esparza R, **Brose MS**. A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer. *Future Oncol*[2]. 2025 Jan; 21(2):169-179.
- Seedor RS**, Aplin AE, Bertolotto C, Carvajal RD, Deacon N, Doble K, Hamid O, Haq R, Kadosh M, Khan S, Kraska J, Lutzky J, McKean M, Montazeri K, Moser J, Onken M, **Orloff M**, Sacco JJ, Smalley K, Selig SM. Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023. *Pigment Cell Melanoma Res*[2]. 2025 Jan; 38(1):e13205.
- Burke-Garcia A, Cutroneo E, Afanaseva D, Madden K, Sustaita-Ruiz A, Selvan P, Rivera Sanchez E, **Leader A**. Findings from a qualitative analysis: Social media influencers of color as trusted messengers of HPV vaccination messages. *PLoS One*[2]. 2025 Apr 4; 20(4):e0319160.
- Bach CA, Hossain MN, Chaudhari IJ, Verrillo CE, Naranjo NM, Amoroso I, Testa A, Sey S, **Kelly WK**, Bellis SL, Lorico A, Blidner AG, Rabinovich GA, Languino LR. A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. *PLoS One*[2]. 2025 Sep 12; 20(9):e0329014.
- Padia SA, Modi S, Wehrenberg-Klee E, Adamo RD, Ahmed A, **Orloff M**, Helmerhorst HJF, Chmielowski B, Ozkan OS, Burgmans MC, Grözinger MG, Lewandowski RJ, Krishnasamy VP. Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion. *J Vasc Interv Radiol*[2]. 2025 Oct 23.
- Phan L, **Wen KY**, Kim HJ, Barta JA, **Juon HS**. Sociodemographic and psychosocial characteristics of e-cigarette ever-use: U.S. HINTS 6 Survey. *Prev Med Rep*[2]. 2025 Jul; 55:103113.
- Song Y, **Sifat M**, Phan L, Banks J, Melillo R, **Leader AE**. Sociodemographic Correlates of Cancer-Related Beliefs Among Chinese Speaking Adults in Greater Philadelphia. *J Racial Ethn Health Disparities*[2]. 2025 Jul 25.
- Juon HS**, Yang D, Fang CX, Hann HW, Bae H, Chang M, Klassen AC. Perceived HBV-Related Stigma Is Associated With Lower Antiviral Medication Adherence in Patients With Chronic Hepatitis B. *J Viral Hepat*[2]. 2025 Mar; 32(3):e70010.
- Leader AE**, Godbolt JB, Crumpler N, Gross L, Hartman R, Keith SW, Giri VN. Utilizing peer educators to increase genetic testing for prostate cancer among black males: results of a randomized controlled trial. *J Natl Med Assoc*[2]. 2025 Aug; 117(4):248-257.
- Freeman TJ, George TJ, Jacobs SA, Yothers G, Kolevska T, Feng H, Lipchik C, Maley S, Song N, Srinivasan A, Finnigan M, Wade JL, Buchschacher GL, Al Baghdadi T, Shipstone A, **Lin D**, Puhalla SL, Allegra CJ, Wolmark N, Pogue-Geile KL. NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated. *Cancer Chemother Pharmacol*[2]. 2025 Aug 09; 95(1):80.
- Lee G, **Juon H**, Kim E, Smith KC, Hann HW, Chang M, Klassen AC. HBV Transmission Knowledge Among Korean-American Chronic Hepatitis B Patients in the United States. *J Community Health*[2]. 2025 Apr; 50(2):306-316.
- Schlegel LE, Brill-Edwards M, Wang ZX, **McNair C**, Gargano S, Cottrill E. Detection of PTEN Mutations in Fine Needle Aspiration Biopsies of Indeterminate Thyroid Nodules: Impact on Diagnosis and Prognosis. *Head Neck*[2]. 2025 Aug; 47(8):2145-2151.
- Cognetti DM, Curry JM, **Johnson J**, Kwon M, Su SY, Civantos F, Olazagasti C, Valentino J, Arnold SM, Bell RB, Gibson MK, Mannion K, Van Abel KM, Price KA, Dong H, Thorne AH, Suzuki T, Gillenwater AM. Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. *Head Neck*[2]. 2025 Aug 25.
- Leader AE**, Song Y, González ET, Fortune T, Graciani N, Zeigler-Johnson C, Glanz K. Developing a city-wide, community-engaged cancer disparities research agenda. *Cancer Causes Control*[2]. 2025 Jan; 36(1):45-50.
- Hemler JR, Wagner RB, Sullivan B, Macenat M, Tagai EK, Vega JL, Hernandez E, Miller SM, **Wen KY**, Ayers CA, Einstein MH, Hudson SV, Kohler RE. A Proposed mHealth Intervention to Address Patient Barriers to Colposcopy Attendance: Qualitative Interview Study of Clinic Staff and Patient Perspectives. *JMIR Form Res*[2]. 2025 Jan 14; 9:e55043.
- Melby G, Zeigler-Johnson C, Dicarlo M, Pham K, Shusted CS, **Myers R**. Developing a Strategy to Increase Lung Cancer Screening in Areas of Need.

- Popul Health Manag*[2]. 2025 Feb; 28(1):15-21.
- Murray RM, Chiang SC, Klassen AC, Manganello JA, **Leader AE**, Lo WJ, Massey PM. Developing an Online Community Advisory Board (CAB) of Parents From Social Media to Co-Design an Human Papillomavirus Vaccine Intervention: Participatory Research Study. *JMIR Form Res*[2]. 2025 Apr 16; 9:e65986.
- Trieu P, Fetzer D, McLeod B, Schweickert K, Gutstein L, Egleston B, Domchek S, Fleisher L, Wagner L, **Wen KY**, Cacioppo C, Ebrahimzadeh JE, Falcone D, Langer C, Wood E, Karpink K, Posen S, Selmani E, Bradbury AR. Developing the MyCancerGene Digital Health Portal to Improve Patients' Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study. *JMIR Form Res*[2]. 2025 May 14; 9:e56282.
- Zhang J, **Wen KY**, Liang J, Diamond V, Dayaratna S. Feasibility and Acceptability of Human Papillomavirus Based Self-sampling in Underserved Minorities in the United States: A Scoping Review. *J Low Genit Tract Dis*[2]. 2025 Oct 01; 29(4):348-358.
- Guan M, Chiang SC, Murray RM, Lo WJ, Hill LT, Klassen AC, Manganello JA, **Leader AE**, Massey PM. Narratives or not? Examining the roles of message format and individuals' stages of change in the context of HPV vaccination promotion. *Health Educ Res*[2]. 2025 May 12; 40(3).
- Jeminiwa R, Dadabaev F, Kim H, Gannon M, **Myers R**, Abatemarco DJ. Perspectives of physicians and doulas on shared decision-making and decision counseling in the treatment of pregnant women with opioid use disorders. *J Subst Use Addict Treat*[1]. 2025 Jan; 168:209526.
- Wei S, Patchefsky AS, Pei J, Brown SA, **Basu Mallick A**, Wang Z, Jiang W. PHF1::TFE3-positive fibromyxoid sarcoma? Report of 2 cases and review of 13 cases of PHF1::TFE3-positive ossifying fibromyxoid tumor in the literature. *Am J Clin Pathol*[1]. 2025 Feb 12; 163(2):224-230.
- Harris TB, Givens RH, **Lopez A**, Tariq S, Knight N, Hackworth JM, Brown ET, Fanning LG, Núñez A, McNeal-Trice K. Women of Color and Intersectionality Initiative: A Workgroup Report on the Continued Need to Support and Retain Women of Color. *J Womens Health* (Larchmt) [1]. 2025 May; 34(5):581-587.
- Plummer MJ, DiMaria-Ghalili RA, **Lopez AM**, Fang CY, Coe CL, Surachman A. Educational attainment, health locus of control and inflammation among cancer survivors in the Midlife in the United States (MIDUS) study. *Psychol Health Med*[1]. 2025 Oct 29:1-22.
- Charnysh E, McCain S, Truhlar A, Pal S, Reader JM, Sanghavi K, Uhlmann WR, Hendy K, **Leader A**, Blasco D, Prince AER, Feero WG, Brandt R, Giri VN, Lee C, Roberts JS. Perceived understanding and psychosocial outcomes: employees' responses to learning results of workplace genetic testing. *Per Med*[1]. 2025 Aug; 22(4):211-221.
- Nassur J, Dajee D, **Leader A**, DiSantis K. Barriers to Breast, Cervical, and Colorectal Cancer Screenings Faced by Refugees Resettled in the United States: A Rapid Review. *J Immigr Minor Health*[1]. 2025 Aug; 27(4):609-622.
- Manganello JA, Murray RM, Lo WJ, Chiang SC, Guan M, Klassen AC, **Leader AE**, Hill LT, Massey PM. Differences in HPV Vaccine Information Usefulness and Understanding Between Parents With and Without a Child with Special Healthcare Needs. *Matern Child Health J*[1]. 2025 May; 29(5):686-695.
- Tagai EK, Bradley M, **Wen KY**, Hernandez E, Miller SM. Type of Social Support for Smoking Cessation Among Low-Income Postpartum Women. *Int J Behav Med*[1]. 2025 Aug; 32(4):640-645.
- Tucker M, Hovern D, Liantonio J, Collins E, **Binder AF**. End of Life Outcomes Following Comfort Care Orders: A Single Center Experience. *Am J Hosp Palliat Care*[1]. 2025 Apr; 42(4):321-325.
- Adefarati O, Yearwood R, Song Y, **Leader AE**, Glanz K, Gonzalez ET, Keith SW, Graciani N, Fortune T, Zeigler-Johnson CM. The Impact of a Community Partner Research Training Program. *J Cancer Educ*[1]. 2025 Aug 22.
- Arai Y, Brazauskas R, He N, Al-Homsi AS, Chhabra S, Battiwalla M, Yanada M, Steinberg A, Diaz Perez MA, Hong S, Kanda J, Bashey A, Frangoul HA, Badawy SM, Verdonck LF, Lazarus HM, Yared JA, Hashem H, Sharma A, Aljurf M, Dias AL, Abid MB, Wirk B, Freytes CO, Zeidan AM, **Gergis U**, Beitinjane A, Askar M, Pu JJ, Lehmann LE, Rangarajan HG, Wood WA, Hashmi S, Yano S, Kako S, Ozawa Y, Doki N, Kanda Y, Fukuda T, Katayama Y, Ichinohe T, Tanaka J, Teshima T, Okamoto S, Atsuta Y, Saber W. Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An

International Collaborative Study. *EJHaem*[1]. 2025 Jun; 6(3):e70061.

Miles A, Evers-Hunt H, Naik A, Dimarco R, Donnelly A, Deveney B, Fala N, Thomas C, **Binder AF**. Evaluating a Sepsis Screening Tool in the Outpatient Setting. *Clin J Oncol Nurs*[1]. 2025 Aug 04; 29(4):297-302.

Kasner MT, Courtenay-Luck N, Dinardo C, Post SM, Baratam P, Magrath GN, Nakamura T, Fujii A, Prados S, Honda N, McBride M, Edwards-Holmes P, Stuart R. Anexelektio (Axl)/Mer inhibitor tamnorzatinib in patients with relapsed/refractory acute myeloid leukaemia: Results from a phase I (monotherapy) and phase II (combination with venetoclax) clinical study. *Acta Haematol*[1]. 2025 Dec 12:1-18.

Christensen D, Belair JA, **Basu-Mallick A**, Brown SA, Klein M, Jiang W. Synchronous Low-Grade Central Osteosarcoma and Ewing Sarcoma: A Rare Case Report. *Int J Surg Pathol*[1]. 2025 Feb; 33(1):131-137.

Leung SS, Gonsalves CF, **Orloff M**, Adamo RD, Lindenmeyer CC, Eschelman DJ. Percutaneous Hepatic Perfusion Melphalan Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)

in a Patient with Metastatic Uveal Melanoma. *Case Rep Oncol*[UK]. 2025; 18(1):1145-1151.

Cocozza T, Smith R, **Lopez AM**, Rudoler S, Slamon R, Zhan T, Vega JL, Dhamankar M, Padmanabhan A, Miller SM, **Wen KY**. Multilevel Factors Influencing Perceived Barriers to Adjuvant Endocrine Therapy Among Breast Cancer Patients at Medication Onset. *Int J Environ Res Public Health*[UK]. 2025 May 06; 22(5).

Jeurkar C, Majeed A, Wilde L, Keiffer G, Kasner M. A Century of Hypomethylating Agent: A Remarkable Response to Azacitidine Monotherapy for Relapsed Acute Myeloid Leukemia - A Case Report. *Case Rep Oncol*[UK]. 2025 May 15; 18(1):575-581.

Gowin K, Ahn ER, **Lopez AM**. Synthesis and Educational Overview of the ASCO-Society of Integrative Oncology Guidelines: On the Path to Implementation. *Am Soc Clin Oncol Educ Book*[UK]. 2025 Jun; 45(3):e471830.

Melillo RJ, **El Khoury C**, Godbolt JB, Greene Q, Bussard KM, **Leader AE**. Increasing community members' engagement in cancer research: the making research CLEAR program. *Res Involv Engagem*[UK]. 2025 Jun

19; 11(1):68.

Najar H, Evans J, Vedula S, **Keiffer G**, Zhang J. Acute kidney injury after treatment with arsenic trioxide. *Clin Nephrol Case Stud*[UK]. 2025; 13:84-88.

Simone NL, Burke S, Hamade K, **Leader A, McNair C**. Mapping disparities: identifying cancer care gaps in sexual and gender minority patients. *J Natl Cancer Inst Monogr*[UK]. 2025 Jul 01; 2025(69):153-160.

Fradin JJ, Riley JM, Storozynsky E, Tchantchaleishvili V, **Wilde LR**. Nonbacterial Thrombotic Endocarditis as a Presenting Paraneoplastic Manifestation of Acute Promyelocytic Leukemia. *JACC Case Rep*[UK]. 2025 Jul 16; 30(19):104043.

Stezzi M, **Brose M, Gordon SW**, Solomides C, Tuluc M, Miller J. Well-Differentiated Lung Neuroendocrine Tumor Masquerading as Metastatic Medullary Thyroid Cancer. *JCEM Case Rep*[UK]. 2025 Sep; 3(9):luaf172.

Adelba Torres, Rakhee Vaidya, Fernando Vargas Madueno, Sami Ibrahimi, Seema Naik, Mitul Gandhi, Julie Haydu, **Bradley Lash**, Mark Fesler, John Hrom, Eric Lee, Suchitra Sundaram, Kristin Conte, Kojo Osei-Bonsu, Yang Bai, Christian Eskelund, Alexander Boardman, Ralph

Vincent Boccia, Christina Lee, David Andorsky, Jeff Sharman. Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity. *Blood* 2025; 146 (Supplement 1): 1959. doi: <https://doi.org/10.1182/blood-2025-1959>

Mallorie L Huff, **Ranju Gupta**, Rahul Gupta, Kelly C Schadler, Shae Duka, Vienna Histon-Figliolini, Joshua Kalter, Amogh M Joshi, Nadeem V Ahmad, Wilbert S Aronow 3, Deborah W Sundlof. A retrospective analysis of the association of obesity with anthracycline- and trastuzumab-induced cardiotoxicity in the treatment of breast cancer and lymphoma. *Affiliations Expand PMID: 40741241, PMCID: PMC12305517, DOI: 10.5114/aoms/190869*

Aatma Ram, Chun T Siu, Abir Mukherjee, **Ranju Gupta**. Osimertinib-Induced Myositis in a Patient With Metastatic Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation. *PMID: 39310509, PMCID: PMC11416797, DOI: 10.7759/cureus.67597*

Mitchell AP, Salner A, **Palyca P**, Farooki A, Persaud S, Chakraborty N, Bhamidipati D, Klimchuk

M, Dinan MA, Leapman MS, Lipitz-Snyderman A, Hamid A, Ostroff JS, Morris MJ. Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer. *JCO Oncol Pract*. 2025 Nov 3:OP2500457. doi: 10.1200/OP-25-00457. Online ahead of print.

Autio KA, Kyriakopoulos CE, **Palyca P**, Xiao H, Enamekhoo H, Danila D, Jan M, Catharine V, Riedel E, Devitt M, Laird AD, Scher HI. A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes. *Invest New Drugs*. 2025 Aug;43(4):924-932. doi: 10.1007/s10637-025-01580-1. Epub 2025 Sep 4. PMID: 40906325

Thomas J Kaley, Christian Grommes, Elizabeth Coffee, Robert J Young, **Tara Morrison**, Ahmad Daher, Lauren R Schaff, Yufei Deng, Subhiksha Nandakumar, Eli L Diamond, Lisa M DeAngelis, Katherine S Panageas, Igor Gavrilovic, Andrew Lin, Elena Pentsova, Jacqueline Stone, Bianca D Santomaso, Anna F Piotrowski, **Suresh Nair**, Nikolaus Schultz, Anne S Reiner, Ingo K Mellinghoff. Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma. *Neuro-Oncology*, 2025

Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli HJ, Rojas C, Gross-Goupil M, Schinzari G, Melichar B, Barthélémy P, Ruiz Garcia A, Sosman J, Grimm MO, Goh JC, Suarez C, Kollmannsberger CK, **Nair SG**, Shuch BM, Huang J, Simsek B, Spiridigliozzi J, Lee CW, van Kooten Losio M, Grünwald V. Adjuvant Nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: Part B of the randomized, placebo-controlled, Phase III CheckMate 914 Trial. *J Clin Oncol*. 2025 Jan 10;43(2):189-200. doi: 10.1200/JCO.24.00773. Epub 2024 Sep 20. PMID: 39303200

Hafeez Z, Johnson A, Nester N, et al. (February 26, 2025) Impact of Adopting a Multidisciplinary Care Delivery Model on Treatment Effectiveness and Outcomes in Stage III Melanoma Patients at a Community-Based Academic Institution: A Retrospective Study. *Cureus* 17(2): e79703. doi:10.7759/cureus.79703

Jayalath VH, Assel M, Iyer G, Niglio S, Bochner BH, Dalbagni G, Donat SM, Herr HW, Cha EK, Donahue TF, Pietzak EJ, Hakimi AA, Kim K, Al-Ahmadie HA, Vargas HA, Ghafoor S, Benfante NE, Rodriguez DV, Meyerson AR, Meraney AM, Shichman SJ, Kamradt JM, **Nair SG**, Baccala AA Jr, **Palyca P**, **Lash BW**, **Rizvi MA**, Swanson SK, Muina AF, Apolo AB, Rosenberg JE, Bajorin DF, Coleman JA. Neoadjuvant chemotherapy for high-risk localized upper tract urothelial carcinoma: Final long-term outcomes from a phase 2 clinical trial and an expanded cohort. *Eur Urol*. 2025 Sep 25:S0302-2838(25)00503-2. doi: 10.1016/j.eururo.2025.08.012. Online ahead of print. PMID: 41006098

Mani H, **Nair S**. Sotorasib provides a durable response in high-grade metastatic ovarian serous adenocarcinoma harbouring KRAS G12C mutation. *BMJ Case Reports* CP2025;18:e266618. <https://doi.org/10.1136/bcr-2025-266618>

There were 154 publications authored by Medical Oncology Faculty Members from 01/01/2025 to 12/31/2025. 36 publications (23.38%) were intra-departmental collaborations.

Omitting Journals with an Undefined Journal Impact Factor

26 publications(17.93%) had an Journal Impact Factor ≥ 10
 26 publications(17.93%) had an Journal Impact Factor ≥ 9
 62 publications(42.76%) had an Journal Impact Factor ≥ 5

Average Journal Impact Factor = 5.26



21. Bottles, "Patient Medicines"

Various

Late 19th and early 20th centuries

Edward Squibb (MD 1846) founder of the early pharma giant Squibb & Sons, was a crusader in making drugs uniformly safe. His warning reports to US Congress (as early as 1864) resulted in the landmark 1906 Pure Food and Drug Act. This would eventually put an end to harmful proprietary medicines made from mystery ingredients.





Cover Photo of Thomas Jefferson University Hospital ©Thomas Jefferson University Photography Services

Jefferson Department of Medical Oncology

1100 Chestnut Street, 14th Floor

Philadelphia, PA 19107

Phone: 215-955-8874

JeffersonHealth.org/Clinical-Specialties/Medical-Oncology